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Abstract 
Introduction 
Optimal adherence to antiretroviral (ARV) is essential for preventing mother-to-child 
transmission of HIV. Since the Zambian government has revised the national guidelines 
in 2010, no studies have assessed ARV adherence. This study aimed to examine a 
probability of adherence to ARV and identify the risk factors for non-adherence in the 
PMTCT program. 
Methods 
A prospective cohort study was conducted in Chongwe district, from June 2011 to 
October 2012. Four-days self-report ARV adherence was assessed among 321 HIV-
positive mothers during pregnancy, 1 week, 6 weeks, and 24 weeks postpartum. 
Probability of adherence was calculated using Kaplan-Meier survival methods, and Cox 
proportional hazard regressions were performed to identify risk factors for non-
adherence controlling for the effects of loss to follow-up.  
Results 
A high incidence of non-adherence was observed in HIV-positive mothers. Especially, 
mothers attending referral health center were more likely to be non-adherent, compared 
x 
 
with mothers attending primary health centers (PHCs) with ART services (hazard ratio 
(HR): 0.71, 95% CI: 0.57-0.88) and those attending PHCs without ART services (HR: 
0.58, 95% CI: 0.46-0.74). Mothers newly diagnosed as HIV-positive showed a higher 
risk for non-adherent (HR: 1.24, 95% CI:1.03-1.50). 
Conclusion 
This study found poor ARV adherence in the PMTCT program due to high incidence of 
loss to follow-up. Expanding ART services at all PHCs should be considered. Early 
HIV testing and treatment before pregnancy and couple HIV testing and counseling are 
potential strategies to improve adherence to the PMTCT program.  
 
Key words 
Prevention of mother-to-child transmission of HIV (PMTCT), Antiretroviral (ARV), 
Adherence, HIV care, Pregnancy
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1: Introduction 
1-1. Global situation of HIV/AIDS 
1-1-1) HIV Epidemic 
The global HIV/AIDS epidemic is a leading cause of death. The number of 
people who were newly infected with HIV was 2.7 million, and the number of people 
who died due to AIDS-related diseases was 1.8 million in 2010 (1). People living with 
HIV (PLWH) has continued to increase, reaching 34 million in 2010 due to reductions 
in AIDS-related deaths (1). Sub-Saharan Africa carries the highest burden of HIV: the 
proportion of PLWH in this region alone accounted for 68% of the global population of 
PLWH; 70% of new HIV infections; and 67% of AIDS-related deaths in 2010 (1). Such 
HIV epidemic has been a substantial barrier to socio-economic development in sub-
Saharan Africa. 
 
1-1-2) Children and HIV/AIDS 
Infants are at risk of acquiring HIV from the mother in the uterus, during the 
birthing process, and through breastfeeding (2). Among breastfeeding infants, an 
estimated 20 to 25% of HIV transmission occurs in utero, 40 to 55% during labor and 
delivery, 20 to 25% at first two months of life, and 5 to 10% after two months of age (3). 
Breastfeeding causes an additional risk depending on maternal viral load, advanced 
immune deficiency, prolonged rupture of membranes, and mastitis (3). Over 90% of 
pediatric HIV attributes to mother-to-child transmission (2). If any antiretroviral (ARV) 
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intervention is not used, 15 to 30% of non-breastfeeding infants and 30 to 45% of 
breastfeeding infants will be at risk of HIV infection (2, 3).  In 2010, about 3.4 million 
children under 15 years were estimated to be living with HIV, 390,000 were newly 
infected, and 250,000 died from AIDS-related causes (1). About 90% of the HIV-
positive children were living in sub-Saharan African countries (1). Meanwhile, 
improved access to HIV care and treatment has reduced 30% of new pediatric HIV 
infections from 2001 to 2010, and also 30% of AIDS-related deaths from 2005 to 2010 
(1). 
 
1-1-3) Global response to HIV/AIDS  
Combating HIV/AIDS is one of the prioritized targets outlined in the 
Millennium Development Goals. In 2001, the United Nations General Assembly 
Special Session on HIV/AIDS called for a global commitment to an expansion of 
antiretroviral therapy (ART) and prevention of mother-to-child transmission of HIV 
(PMTCT) (1, 4). An increasing demand for fundraising in HIV services spawned the 
Global Fund in 2002, followed by the United States President’s Emergency Plan for 
AIDS Relief in 2003 (1, 4). Meanwhile, the “3 by 5” and universal access initiatives 
have accelerated scale-up of HIV prevention, treatment, care and support for 
tuberculosis patients with HIV, injecting drug users, sex workers, men who have sex 
with men, pregnant women, and children exposed to HIV in low- and middle-income 
countries (1, 5). In 2010, WHO revised the guidelines for ART to promote early 
initiation with an efficacious regimen (6-8).  Recent research has built evidence that 
ART can significantly suppresses viral load and reduce the risk of HIV transmission 
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from mother to child (9-17) and from HIV-positive partner to HIV-negative partner, 
delay onset of opportunistic infections and AIDS (18), and prevent tuberculosis disease 
in HIV-positive individuals (19). Based on such evidence, ART can now play an 
important role in “treatment as prevention”: using ART as a HIV prevention method 
that significantly reduces the risk of HIV transmission (20).  The WHO and UNAIDS 
undertook the Treatment 2.0 initiative in 2011, which aims to achieve and sustain 
universal access to ART through expanding point-of-care diagnostics, optimal ARV 
regimens and other HIV care and treatment services at lower cost, and mobilizing 
community support (4).  The major targets of the Treatment 2.0 initiative are to: 1) 
eliminate new pediatric HIV infections; 2) decrease tuberculosis-related deaths in 
people living with HIV by half; and 3) provide ART to 15 million people in need (4). 
Thus, the PMTCT program has emerged as a substantially prioritized target for its great 
potential to reduce the global burden of HIV/AIDS. 
 
1-1-4) PMTCT program 
The PMTCT program was launched globally in 1998 (2). Since 2011, the 
PMTCT program has been oriented toward eliminating new pediatric HIV infections 
and improving maternal and child health and survival (21). To these ends, a four-
pronged approach has been taken: 1) primary prevention of HIV infections in young 
women and reproductive-aged women; 2) family planning to prevent unintended 
pregnancy; 3) ARV interventions for prevention of vertical transmission to infants; and 
4) assuring linkages to care, treatment and follow-up (21). Of the four approaches, ARV 
interventions can make a direct impact on reduction of mother-to-child transmission (9-
17). 
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 To minimize mortality and morbidity in HIV-exposed or –infected infants, the 
PMTCT program generally adopted a six-combination intervention from pregnancy to 
breastfeeding period: 1) antenatal HIV testing and counseling; 2) ARV provision to 
pregnant women diagnosed as HIV-positive; 3) ARV provision for infants born to HIV-
positive mothers; 4) early diagnosis of HIV infection among infants; 5) co-trimoxazole 
provision for HIV-exposed children; and 6) provision of HIV care and treatment to 
HIV-positive children (1). Opt-out HIV counseling and testing is the initial step in these 
interventions, as it can identify HIV-positive pregnant women who could receive crucial 
benefits from ARV intervention for improving their own health and protecting their 
infants from HIV (22, 23). HIV-positive mothers or their infants need to receive ARV 
as long as the infants are exposed to the risk of HIV transmission (7). HIV testing is 
recommended for these children by 4-6 weeks of age, which is essential to facilitate 
immediate initiation of ART and increase survival of HIV infected infants (24-26). 
Since access to pediatric HIV care and treatment are limited in high HIV burden 
countries, the use of co-trimoxazole prophylaxis can reduce the risk of diseases 
progression and death in HIV-positive children until they initiate ART (27-31). For such 
benefits, all HIV-exposed infants take co-trimoxiazole until breastfeeding is completely 
terminated and HIV status is confirmed to be negative (31).  
 
1-1-5) Scale-up of ARV interventions in the PMTCT program 
The first PMTCT guidelines on ARV intervention were released by WHO in 
2000, later updated in 2004 (32), 2006 (33), and 2010 (7) as the efficacy and safety of 
ARV regimens were confirmed. A meta analysis of clinical trials conducted in African 
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countries showed significant efficacy of ARV intervention with transmission rate of 
10.6% in intervention arms versus 21.0% in placebo arms (11). Increased ARV 
coverage has also facilitated a great reduction in mother-to-child transmission at 
population level. In 2010, for example, 48% of mothers received ARV (excluding 
single-dose nevirapine [sd-NVP]), 34% of pregnant women eligible for ART received 
treatment, and 42% of infants received ARV for prophylaxis in low- and middle-income 
countries (1). As a result, the mother-to-child transmission rate was reduced from 35% 
to 26% in low- and middle-income countries during the past decade (1). In non-clinical 
trial settings, ARV interventions also demonstrated a great reduction in the rate of 
mother-to-child transmission in high HIV prevalence countries (34-38).  
 
1-1-6) WHO 2010 ARV guidelines for PMTCT 
The 2010 WHO ARV guidelines were developed to utilize more efficacious 
ARV interventions in resource-limited settings (7). Proper implementation of the 
guidelines would reduce the risk of HIV transmission to less than 5% among 
breastfeeding infants and to less than 2% among non-breastfeeding infants, and will 
improve maternal and child survival (7). The guidelines recommend two new 
approaches: 1) HIV positive women eligible for treatment early initiate lifelong ART 
for preventing HIV transmission and improving their own health, and 2) HIV positive 
women not eligible for lifelong treatment take ARV prophylaxis to reduce the risk of 
HIV transmission to their infants from pregnancy, delivery to breastfeeding period (7). 
The major differences from the 2006 guidelines are ARV eligibility criteria for 
prescribing treatment or prophylaxis regimen, timing of commencement of antenatal 
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ARV prophylaxis, and ARV prophylaxis regimen for HIV-exposed infants (7) 
(Appendix 1). 
The 2010 guidelines recommend two ARV regimen options: Option “A” and 
Option “B” (Appendix 2). Both options recommend that pregnant women with CD4+ 
lymphocyte (CD4) counts less than 350 cells/mm
3
 or at clinical stage 3 or 4 commence 
a lifelong ART regimen, and pregnant women not eligible for treatment commence an 
ARV prophylaxis regimen (7). For mothers not eligible for treatment, Option A 
recommends initiation of zidovudine (AZT) from 14 weeks of gestation, sd-NVP at 
labor, and the addition of lamivudine from delivery to 7 days post-delivery (7). Option 
B recommends initiation of triple ARVs prophylaxis from 14 weeks of gestation until 
the one week after completing breast-milk (7). For infants, Option A recommends that 
breastfed infants ingest NVP from birth to 1 week after the complete weaning of breast-
milk, non-breastfed infants ingest sd-NVP plus AZT or NVP for the first 4 - 6 weeks, 
and infants born to mothers on ART are administered NVP or AZT for the first 4 - 6 
weeks, while Option B suggests that infants take NVP or AZT only for the first 4 - 6 
weeks since mothers take ART (7). Both options are equally efficacious in pregnant 
women with CD4 counts over 350 cells/mm
3 
(39). However, Option A is advantageous 
in resource-limited countries, due to lower drug costs and dispensing of the same ARV 
drugs used in the 2006 guidelines (39).  
Guidelines for feeding practices were also updated in 2009. Mothers living with 
HIV are recommended to undertake exclusive breastfeeding from birth to 6 months, 
then introduce supplementary food, and continue breastfeeding until 12 months (7, 40). 
To maximize the efficacy of the guidelines, both mothers and their infants need to be 
adherent to ARV medication and feeding practice, otherwise failure to adhere to the 
7 
 
guidelines may increase the risk of malnutrition, morbidity and mortality caused by HIV 
and other infectious diseases (9, 16, 40, 41). The guidelines offer the opportunity to 
control mother-to-child transmission, if it can be implemented properly. However, 
multiple operational challenges occur in resource-limited countries with a high burden 
of HIV, such as the Republic of Zambia (Zambia). 
 
1-2. HIV/AIDS in Zambia 
1-2-1) Epidemiology 
Zambia is one of the highest HIV prevalence countries. It is located in the southern part 
of Africa, with a population of 13 million in 2010 (42). The first case of HIV infection 
was reported in 1984, after which HIV prevalence rapidly grew to a peak of 16% in the 
mid-1990s (43). HIV/AIDS is the top-ranked cause of years of life lost (YLLs), 
accounting for 15% of all YLLs in 1990, and increasing to 20% of all YLLs in 2010 
(44). In 2007, HIV prevalence among adults aged 15-49 years was about 14% (42). 
Over 900,000 people were estimated to be living with HIV/AIDS, about 80,000 of 
whom were newly infected, and the total number of AIDS-related deaths was about 
42,000 in 2009 (43). Casual sex (defined as “sex with multiple partners as well as with 
partners who are neither spouses nor cohabiting”) is a major cause of HIV infection, 
accounting for more than 70% of new infections (42, 45). An estimated 23% of adults 
aged 15-49 years were tested for HIV in 2009 (42). Men were more likely to have 
multiple and/or concurrent partners than women (14% compared to 1%), and 27% of 
men and 33% of women reported condom use in sexual intercourse with multiple and/or 
concurrent partners (42). 
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1-2-2) Pediatric HIV/AIDS in Zambia 
Mother-to-child-transmission is a major cause of pediatric HIV infection in 
Zambia. HIV infections in children under 14 years accounts for 10% of all HIV 
infections in Zambia (43), slightly lower than the average of 13% in sub-Saharan 
African countries (1). However, only 31% of the children received ART in 2010 (46). 
Every year, about 80,000 infants are born at risk of acquiring HIV from their mothers 
(47), and HIV caused an estimated 12% of deaths in children under 5 years in 2010 (46). 
In children aged less than 14 years, the number of new infections has fallen from 21,189 
in 1996 to 9,196 in 2009 (43). Estimated AIDS-related child mortality also decreased 
from 14,681 in 2003 to 7,282 in 2009 (43). Although progress has been made on 
reducing new pediatric HIV infections and related deaths, further effort is needed to 
achieve the goal of eliminating new pediatric infections by 2015. A key to this effort is 
further scale-up of the PMTCT program across the country. 
 
1-2-3) The PMTCT program in Zambia 
Zambia introduced the PMTCT program in 1999, and has been rapidly scaling 
up over the past decade (47). Such efforts reduced the incidence of mother-to-child 
transmission from 24% in 2009 to 11% in 2011 (46). In 2011, 97% of pregnant women 
underwent HIV testing, and 85% of HIV-positive pregnant women received ARV (42). 
Of the available ARV regimens, 11% of women received only sd-NVP, 75% were 
prescribed a AZT prophylaxis regimen, and 14% had taken ART in 2011 (42). Uptake 
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of PMTCT services in infants born to HIV-positive mothers remains limited, compared 
with HIV-positive pregnant women. In 2011, only 36% of the infants received ARV, 
37% received co-trimoxazole, and 27% underwent virological HIV testing within two 
months of age (42).  
The new national guidelines (Appendix 3) were developed by the Zambian 
Ministry of Health in 2010 based on Option A of the WHO 2010 guidelines, and 
introduced across the country in 2011(47).  However, several challenges in adherence to 
the PMTCT program have emerged. For example, delayed first antenatal attendance 
may cause mothers to start ARV later than the recommended timing of 14 weeks 
gestation, because the first antenatal clinic attendance occurs at an average 20 weeks 
gestation (48). Continuing ARV prophylaxis until the end of breastfeeding can also be 
difficult for mothers not eligible for treatment as only half of mothers attend postnatal 
check-up (48).  Barriers to providing full PMTCT services include poor geographical 
accessibility, lack of male involvement, limited access to early infant diagnosis, human 
resource shortages, stock-out of ARVs, and poor linkages from PMTCT to further 
examination and treatment at ART clinics (43).  
 
1-3. ARV adherence 
1-3-1) Importance of assessing ARV adherence 
ARV interventions for PMTCT should not be evaluated only by ARV coverage 
at the population level. It should be also evaluated by ARV adherence at individual 
level for the period that infant is exposed to a risk of HIV transmission. This is because 
adherence should be strictly observed in order to maximize treatment benefits for 
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reducing viral load, and preventing drug resistance (49-51). For PMTCT, suppressed 
maternal viral load can significantly contribute to improve maternal health and reduce 
the risk of vertical transmission to infants (52). Although few studies have reported 
optimal levels of ARV adherence for PMTCT, a minimum 95% level of adherence is 
generally required to maintain virologic suppression (53, 54). 
 
1-3-2) ARV adherence in various populations 
ARV adherence has been examined in various target populations and study 
settings, using different measurements. Two meta-analyses on ARV adherence reported 
that an estimated 74% of pregnant women in low- and middle- income countries 
reached adequate levels of adherence (41), compared with 77% of the general 
population on ART in sub-Saharan African countries (55). Only a few studies have 
compared ARV adherence between pregnant women and non-pregnant women. In 
Brazil, for example, pregnant women showed greater adherence than non-pregnant 
women (56). In South Africa, women who had previously received PMTCT services 
were more likely to be adherent (51). In the meta-analysis of maternal ARV adherence 
in the PMTCT program, pregnancy was the only factor positively associated with 
adherence, possibly due to maternal concerns about fetal health and vertical 
transmission (41). Of the 51 selected studies, however, the majority of studies assessed 
adherence in the antenatal period alone, and only eight studies examined adherence in 
the both antenatal and postnatal periods (41). Of the eight studies, only two studies were 
conducted in sub-Saharan Africa (41, 57, 58). Thus, further investigation is needed to 
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demonstrate ARV adherence during both the antenatal and postnatal period in sub-
Saharan Africa.  
 
1-3-3) Adherence before and after delivery in high-income countries 
Poor ARV adherence rates have been reported in assessments of the pregnancy 
and postnatal periods in the United States (Appendix 4). For example, adherence rates 
in antenatal women were 61 to 80%, and 44 to 66% in postnatal women (59-65). Non-
adherence was associated with minority group membership, residence area, being 
teenaged (59), asymptomatic HIV condition, and having two or more additional 
children (61), daily medication taken more than twice (62), advanced disease stage, 
higher viral load, multiple HIV-related symptoms, alcohol consumption, and times of 
clinical evaluation (65). On the other hand, better adherence was associated with less 
advanced disease stage, feeling happy (64), never having missed a prenatal vitamin dose, 
non-use of illicit drug (60, 64), having a social support network and disclosure of HIV 
status (61, 63). ART initiation before or after pregnancy was inconsistently associated 
with adherence (59, 64). Although these studies provided important evidence about 
ARV adherence for PMTCT in the United States, maternal backgrounds, development 
stage and epidemic context differ between the United States and sub-Saharan African 
countries. Thus, it is important to examine ARV adherence for PMTCT separately in 
sub-Saharan Africa countries.  
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1-3-4) Perinatal adherence in sub-Saharan Africa 
Until the AZT prophylaxis regimen was established, taking sd-NVP by mothers 
and prescribing NVP to their infants had been the proxy indicators for ARV adherence 
in the PMTCT program. A number of studiers have reported a wide range of adherence 
rates: 42 to 94% in mothers, and 24 to 91% in their infants (Appendix 4) (66-75). In 
these studies, home delivery was an especially common risk factor for non-adherence 
(67-69, 72, 75, 76). In Tanzania and Uganda, NVP administration to infants was 
associated with older maternal age, secondary school education, Catholic religion, and 
receiving a counseling about PMTCT in a hospital (68). In another study from Uganda, 
women who were aged over 25 to 34 years, who came from the study sites, who visited 
an antenatal clinic at advanced gestation, and who were on ART were more likely to be 
adherent (71). In Kenya, non-adherence was associated with fewer antenatal clinic 
attendance, younger maternal age, and single mothers (69). In the study, adherent 
mothers were more likely to receive ARV for infants (69). In Rwanda, women who 
were not married, who had less educational experience, who had HIV test after first 
antenatal clinic attendance, who attended antenatal clinics fewer times, and who have 
not disclosed their HIV-positive status to someone aside from a partner were less likely 
to be adherent (70). In Zimbabwe, non-adherence was associated with no experience of 
secondary education, multi-parity, and non-disclosure of HIV status, while adherence 
was associated with previous experience of the PMTCT program, and NVP given 
beforehand at an antenatal clinic (72). In South Africa, adherence was associated with 
better knowledge on PMTCT program, full-term delivery, disclosure of HIV status to 
other, talking with partner about NVP, and having asked partner to undergo HIV testing 
(73). In four sub-Saharan countries including Zambia, non-adherence to NVP was 
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associated with maternal age between 26 to 30 years, multi-gravidity, fewer antenatal 
clinic visits, vaginal delivery, and sd-NVP regimen compared with ART (74). 
Additionally, a qualitative study from South Africa showed that elements of health 
workers’ health care performance, such as giving incorrect instructions about 
medication and not supplying NVP tablet, affected non-adherence (77).  
In Zambia, several studies have assessed NVP adherence, and showed a wide 
range of adherence with rates between 43-94% (66, 67, 74, 78-81). Maternal non-
adherence was associated with a longer interval between HIV testing and delivery (66), 
less than high school-level education, lower newborn birth weight (67), illiteracy (78). 
Experience of prior fetal or infant death was associated with higher uptake of NVP (78). 
An intervention to prescribe NVP after testing HIV and assessing sd-NVP adherence in 
labor wards was associated with increased NVP uptake (81). Meanwhile, non-adherence 
in infants was associated with infants who were born at a tertiary hospital, those who 
with lower five-minute Apgar scores, and those who subsequently died within 28 days 
of age (67).  
 
1-3-5) Adherence before and after delivery in sub-Saharan Africa 
Since the ARV prophylaxis regimen was introduced in sub-Saharan Africa in 
recent years, only a few studies have assessed ARV adherence during pregnancy and 
post-delivery (Appendix 4). These studies have shown the various rates of adherence to 
the regimen. In Kenya, a mean adherence level by pill count was 96% under clinical 
trial setting (57). In Tanzania, adherence at a greater than 95% level was reported 
among 50% of pregnant women, 42% of mothers during intrapartum period in hospital, 
14 
 
and 19% of their infants at postpartum at hospital, and only one mother-infant pair over 
the observed period (58). In South Africa, for example, the four-day complete 
adherence rate was 61% in the antenatal and 86% in the postnatal period (82). In 
another study from South Africa, 61% of pregnant women achieved over 95% 
adherence for the entire prophylaxis period (83). In Nigeria, 81% of pregnant women 
achieved adherence at a greater than 95% level (84).  
Disclosure of HIV status was a major concern affecting adherence among 
pregnant women (58, 82-84). In Tanzania, younger maternal age and having no income-
generating activity were risk factors for missing ARV prophylaxis during pregnancy 
(58). Early enrolment in PMTCT services was also a risk factor for missing antenatal 
ARV prophylaxis due to a time gap between the first antenatal clinic attendance and 
ARV initiation after 28 weeks gestation (58). In South Africa, fewer experiences of 
discrimination and presence of partner involvement in the PMTCT were associated with 
ARV adherence (82). On the other hand, misunderstanding of the ARV regimen, ARV 
use by relatives, domestic violence, and poverty influenced non-adherence (83). In the 
intra- and postpartum periods, non-adherence was affected by unsupportive staff 
performance (58). In Nigeria, non-adherent women showed frequently lacked a 
treatment supporter, while adherent women reported high motivation for protecting their 
infants from HIV transmission (84). In Zambia, there is no available study assessing 
adherence before and after delivery. 
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1-3-6) Loss to follow-up in the PMTCT program 
Loss to follow-up has been a crucial concern that undermines adherence to ARV, and 
limits the optimal outcome of PMTCT program (23, 75). In Zambia, poor postnatal 
attendance and low coverage of postnatal PMTCT program (e.g. prescribing ARV 
prophylaxis and virological HIV testing for infants) imply that loss to follow-up is a 
primary challenge in the PMTCT program (42, 48).  In rural Malawi, 80% of pregnant 
women dropped out of the PMTCT program at six months postpartum (85). In Tanzania, 
40% of pregnant women did not return to a hospital after delivery (58). In Ethiopia, 
30% of infants were lost to follow-up by six months post-delivery (86). In Uganda, 62% 
of postnatal mothers did not return to the scheduled PMTCT program at six to eight 
weeks postpartum (87). In South Africa, 40% of HIV-exposed infants were lost to 
follow up within 28 weeks postpartum (88).  Prior attendance to postnatal check-up, 
having phone contact, Christianity (87), and earlier antenatal clinic attendance (88) were 
associated with retention in the postnatal PMTCT program. Despite such high incidence 
of loss to follow-up, few studies have assessed ARV adherence controlling for its 
negative effect on adherence. Thus, the effect of loss to follow-up should be taken into 
account in evaluating PMTCT programs for a more realistic estimation of the outcomes 
(89). 
 
1-4. Justification of the study 
Drug treatment interventions such as ARV prophylaxis and ART are a principal 
strategy for the prevention of mother-to-child transmission of HIV. To maximize the 
efficacy of the ARV intervention, it is crucial for mothers to attend the PMTCT 
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program regularly and take ARV with a sufficient level of adherence. Since the WHO 
2010 guidelines were released, the ARV regimen has been extended for the first time. 
However, Zambia and its neighboring countries have not conducted any longitudinal 
studies on ARV adherence, and no study has ever controlled for the effect of loss to 
follow-up on ARV adherence.  
 
1-5. Objectives of the study  
This study aimed to assess incidence of non-adherence to ARV and to identify 
risk factors for non-adherence in HIV-positive pregnant women and postnatal mothers 
until 24 weeks postpartum under the 2010 national guidelines. To assess adherence 
from the antenatal to postnatal period, the following methods were used:  
1. Probability of adherence to ARV was calculated using Kaplan-Meier 
survival methods;  
2. Cox proportional hazard regression was conducted to identify risk factors 
for non-adherence; 
3. Sensitivity analysis was used to test the effect of time definition on hazard 
ratios. 
17 
 
2: Methods 
2-1. Study design 
This prospective cohort study was conducted to assess maternal ARV adherence 
for PMTCT from pregnancy to 24 weeks postpartum. HIV-positive mothers were 
recruited at anytime from pregnancy to 23 weeks postpartum. They had interviews a 
maximum of four times including during pregnancy (wave 1), 1 week postpartum (wave 
2), 6 weeks postpartum (wave 3), and 24 weeks postpartum (wave 4). These observation 
points were essential points in the PMTCT program when mothers are expected to 
attend a health facility.  
 
2-2. Study sites 
This study was conducted in Chongwe district, Lusaka province, Zambia 
(Appendix 5) from June 2011 to October 2012, in collaboration with Japan International 
Cooperation Agency and National Center for Global Health and Medicine. Chongwe is 
one of 72 districts, which is a semi-rural area located 45 km away from the capital 
Lusaka, with an estimated population of 194,000 in 2011. HIV prevalence among 
pregnant women was 11% in 2008, which significantly declined from 25% in 1994 (90). 
In the 2007 census, the median length of female school education was 7.3 years, 74% of 
women had partial or adequate literacy, and 43% of women were employed (48). Over 
90% of pregnant women attended antenatal clinics with median gestation on the first 
attendance of 5.1 months, 78% delivered at health facility, 67% had postnatal check-ups, 
and 96% have breastfed their newborns (48).  
18 
 
At the beginning of the study, Chongwe district had 39 medical and health 
facilities, including Chongwe referral health center, Mpanshya mission hospital, and 37 
primary health centers (PHCs). Chongwe referral health center supervised 19 PHCs 
located in the western part of the district, Mpanshya mission hospital was responsible 
for supervising seven PHCs situated in the eastern part of the district. The remaining 
five health facilities belonged to a military hospital, and six PHCs were located near 
Lusaka, thus they referred patients to Lusaka for advanced medical services. 
The catchment area of Chongwe referral health center was selected for the study 
site. In this site, Chongwe referral health center and five PHCs offered HIV care and 
treatment services (ART services) for general HIV-positive patients, all of which were 
included in the study. The rest of the 14 PHCs offered PMTCT services but not ART 
services where thus HIV-positive pregnant women were referred to other health 
facilities to receive further care and treatment. Of these, five PHCs were included in the 
study based on the following criteria: being located within 20 km of a neighboring 
health facility with ART services and Chongwe referral health center, and providing a 
full set of PMTCT services and delivery care. The remaining nine health facilities were 
excluded from the study due to small numbers of PMTCT clients, limited PMTCT 
services, and poor accessibility to advanced medical services. The 11 selected health 
facilities were categorized into three groups based on health facility level and 
availability of ARV services: referral health center, five PHCs providing ART services, 
and five PHCs not providing ART services.  
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2-3. PMTCT programs in the study site 
1) Antenatal period 
During the study period, antenatal clinics offered routine PMTCT services at 
maternal and child health (MCH) wards. These services consisted of group pre-test 
counseling, opt-out HIV testing, and individual post-test counseling. Within a few hours 
of rapid HIV testing, results were distributed to each pregnant woman in post-test 
counseling. Pregnant women who were diagnosed as HIV-positive received sd-NVP 
tablet for administration during labor and daily AZT drugs for 30 days. During 
pregnancy, they were recommended to re-attend health facilities for adherence 
counseling and refilling of prescriptions on a monthly basis. These services were 
provided by health care workers and trained volunteer workers such as traditional birth 
attendants (TBA).  
 
2) Labor and delivery period 
HIV-positive pregnant women were informed to deliver at health facilities. 
Women on ARV prophylaxis regimen took sd-NVP, AZT and Lamivudine at labor and 
delivery. Newborn infants received NVP prophylaxis immediately after birth. At 
discharge, mothers received AZT and Lamivudine tablets for seven days for themselves 
and NVP syrup for their infants. Mothers who delivered at home were recommended to 
come back to the health facility with newborns for prescription of ARV drugs within 48 
hours of delivery. 
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3) Postnatal period 
Postnatal ARV protocols were determined by the maternal ARV regimen and 
feeding options. Based on this, health care workers or trained volunteers instructed the 
mothers in postnatal medication and appropriate feeding practice. If mothers were not 
on ART, their infants were given NVP syrup throughout the breastfeeding period. If 
mothers took ART or did not breastfeed, their infants ceased NVP at six weeks of age. 
In addition to NVP prophylaxis, these infants initiated co-trimoxazole from six weeks of 
age. These infants were recommended to take a HIV polymerase chain reaction (PCR) 
testing at six weeks and six months of age. The PCR samples were sent to Kalingalinga 
laboratory in Lusaka. After a few weeks, the referral health center received all test 
results, and health workers from each PHC came to pick up their clients’ results. Then, 
they informed the HIV status of infants to their mothers at the postnatal PMTCT clinic. 
 
4) Referral from PMTCT to ART services 
HIV-positive pregnant women need to be referred to ART clinic for receiving 
further HIV care and treatment. At Chongwe referral health centers, HIV-positive 
women were tested for CD4 count immediately after diagnosis of HIV at MCH wards, 
and referred to an ART clinic. At PHCs with ART services, HIV-positive pregnant 
women were instructed to re-attend health facilities on the day when the ART clinic was 
opened. Then, they were tested for CD4 count on the first ART clinic visit, and received 
care and treatment accordingly. At PHCs without ART services, health care workers 
gave a referral letter to HIV-positive pregnant women, and instructed them to visit the 
nearest ART clinic.  
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The referral health center was the only facility affiliated with a laboratory, where 
CD4 counts were analyzed, and the results were reported to MCH wards through the 
ART clinic. Meanwhile, PHCs with ART services sent CD4 blood samples to the 
Kalingalinga laboratory, and received the result after two or more weeks. Clinical 
information of all ART patients in the district was managed using an electronic database 
system (Smartcare) at Chongwe referral health center, and patient files were stored at 
ART clinics in health facilities. 
All the PMTCT and ART services were provided for free of charge by the 
Zambian government. During study period, the 11 health centers had never run out of 
ARV drugs for mothers and infants. 
 
2-4. Study population 
In the 11 target health facilities, 3744 women were tested for HIV under the 
PMTCT program, and 415 were diagnosed as HIV-positive from January to December 
2011. Selection criteria for the study participants were: (1) those who were living with 
HIV; (2) those who were expected to deliver from January 2011 to September 2012; (3) 
those who received PMTCT services under the new guidelines at enrolment in the 
study; and (4) those who gave written consent to study participation at recruitment. 
Exclusion criteria were: (1) those who had already decided to transfer to different health 
facilities at recruitment; (2) those who were seriously sick; and (3) those with mental 
illness.  Based on these criteria, 389 women were recruited from July 2011 to March 
2012, but 68 mothers were excluded from analysis due to the following reasons: 29 
mothers did not complete any questionnaires; 29 mothers enrolled in the study later than 
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6 months postpartum; 8 mothers had abortion or still births; and 2 mothers had stopped 
breastfeeding at recruitment. Overall 321 mothers were included in the analysis. 
 
 
2-5. Study tools 
This study used interview-based and clinical record-based tools for data 
collection. Structured questionnaires were administered at face-to-face interview, and 
data was also collected from PMTCT-related registers, personal medical files of ART 
clinic patients, and the electronic database of ART clinic patients (Appendix 6). The 
questionnaire was developed using generic tools for HIV-related operational research by 
the WHO (91), the questionnaire utilized in the 2007 Zambia Demographic and Health 
Survey (48), antenatal cards and children’s clinic cards issued by the Zambia Ministry 
of Health, and a self-report instrument for ARV adherence developed by the Adult 
AIDS Clinical Trials Group (92-94).  
Figure 1. Study participants.
A total of 389 women recruited in the study 
68 women excluded from the analysis
- Incompleted questionnaires (n=29)
- Enrolled >6 months postpartum (n=29)
- Had abortion or still birth (n=8)
- Have stopped breastfeeding at recruitement (n=2)
321 women included in the analysis 
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The survey questionnaires collected the following information on maternal 
characteristics: age, educational level, marital status, timing of HIV diagnosis (already 
diagnosed / newly diagnosed), ARV regimen, timing of study enrolment (during 
pregnancy / after delivery), internalized stigma, attitudes regarding taking ARV, 
experience of couple HIV testing and counseling, disclosure of HIV status to partner, 
HIV status of partner, experience of domestic violence (verbal abuse, physical abuse, 
and /or being forced to leave home) (95), travel time to access the health facility, 
breastfeeding status, and ARV adherence of mother and infant. In the analysis, all 
independent variables were treated as binary variables. Continuous variables, such as 
age and travel time to access health facility, were divided at the median. Attitudes 
regarding taking ARV composed of three items: “Taking medication for HIV (ARV) 
can help keep HIV from being passed to the baby”; “The HIV medication that you are 
taking makes you healthier”; and “If you do not take medications for HIV (ARV) 
properly, the medications won’t work as well” (96). ARV-related attitudes were divided 
into two groups by whether a mother agreed with all three items or not. 
The survey questionnaires were developed in English first, translated into 
Nyanja, the major local language in the study site, and back translated into English for 
confirming the accuracy of the original translation. The questionnaires were reviewed 
by Zambian experts on the PMTCT program working for Chongwe District Health 
Office, and the Zambian Ministry of Health. Before initiating the main survey, pilots 
test were conducted at two health facilities in the study area to assess face validity of the 
questionnaire. 
The PMTCT-related registers were also used including the safe motherhood 
register, the integrated counseling register, the delivery register, the MTCT labor ward 
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register, the under five register, and the baby/mother follow-up register. PMTCT-related 
information included gestational age at the first antenatal visit, date and place of 
delivery, birth weight, date of HIV diagnosis, dispense of ARV prophylaxis, HIV status 
of infants, and survival status of mother and infants. The electronic database and 
medical files of ART clinic patients were reviewed to collect information on ART 
services including date of enrolment in ART clinic, assessment of CD4 count, date of 
ART initiation, and ART regimen.  
 
2-6. Operational definition 
1) Adherence to ARV 
This study used a self-report ARV adherence instrument to assess the study 
outcome. ARV adherence can be measured by self-report, electronic drug monitoring, 
pill counts, prescription refilling records, and therapeutic drug monitoring (97). 
Although each measurement has advantages and disadvantages for assessing ARV 
adherence, self-report adherence is a validated instrument and shows good correlation 
with other measurements and HIV viral load (93, 98, 99). In a meta analysis of ARV 
adherence in PMTCT programs (51 eligible studies), about half of the studies used self-
report adherence measurements (41).    
Two ARV adherence questions were cited from the ARV adherence 
questionnaire of the Adult AIDS Clinical Trials Group: 1) the number of days that a 
mother missed doses for four days prior to the interview; 2) the number of days that the 
mother followed a medication schedule during the four days before the interview (92-
25 
 
94).  Since optimal clinical response requires ARV adherence at the 95% level (53, 54, 
91), ARV adherence status was defined as “non-adherence” if a mother has missed any 
prescribed drug, or has not followed their prescribing schedule at least once in the past 
four days to the interview (64, 82). In addition, if a mother was detected as having 
medication interruption at interview, they were defined as non-adherence. As the 
guidelines recommended, mothers on ARV prophylaxis regimen were assessed on the 
basis of their own adherence during pregnancy and adherence in administering NVP to 
their infants during postnatal period. Mothers on the ART regimen were assessed on the 
basis of their own adherence over the assessment period. 
 
2) Loss to follow-up 
This study set three interviews points after delivery including one week 
postpartum (wave 2), six weeks postpartum (wave 3), and 24 weeks postpartum (wave 
4). However, many participants had delayed attendance. Thus, time ranges for 
scheduled observations were provided as follows: 1-5 weeks postpartum for wave 2, 6-
23 weeks postpartum for wave 3, and 24-52 weeks postpartum for wave 4. If a 
participant did not come to the interview within the period, she was treated as lost to 
follow-up for the wave. Loss to follow-up was significantly associated with non-
adherence and treatment failure in a previous study in Zambia (100), thus they were also 
treated as non-adherent in this study. For these subjects, no follow-up intervention was 
provided and thus reasons for missed interviews were not collected. 
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2-7. Data collection 
The core research team consisted of Chongwe district health officers, experts of 
Japan International Cooperation Agency, and the author. The team selected one health 
worker and one trained volunteer in charge of PMTCT program from each health 
facility. The qualifications for the research assistant were completion of secondary 
education, and ability to speak several local languages and English fluently. In June 
2011, the core research team held a two-day workshop to train research assistants about 
study protocol, voluntary participation, confidentiality policy, and data collection. The 
team also conducted on-site training to supervise data collection.  
In the main survey, HIV-positive pregnant women and post-delivery mothers 
were recruited in the study when they attended the PMTCT program. After providing 
written consent for study participation (Appendix 7), they were officially enrolled in the 
study. Face-to-face interviews were conducted with all mothers. At the end of each 
interview, the mothers received the next appointment and a piece of laundry soap for 
appreciation. 
 
2-8. Statistical analysis 
This study followed up participants over a maximum of four interviews: during 
pregnancy (wave1); 1-5 weeks postpartum (wave 2); 6-23 weeks postpartum (wave 3); 
and 24-52 week postpartum (wave 4). The incidence of non-adherence to ARV was 
calculated using the time from the start of an observation to detection of non-adherence 
(the event). Non-adherence events also included losses to follow-up, reported and 
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unreported deaths, and right-censorship at the end of the research period (1 October, 
2012). The final observation point was the wave 4 interview, at 24 weeks postpartum, or 
the research end.  
In this study, subjects could potentially experience the non-adherence event 
more than once during the assessment period, so the data record could contain interval-
censored records. To deal with multiple events, this study adopted the recurrent event 
model (101). In addition, because the exact time of non-adherence was unknown, the 
censorship point was estimated using the midpoint of the previous- and the current 
observations (102). 
In the recurrent event model using midpoint for censorship, an observation was 
terminated at the midpoint of the previous observation and the observation at which 
non-adherence was detected.  If changes in ARV regimen were detected, the 
observation was terminated at the observation point and a new observation period was 
started from the latest observation point. If a participant did not attend a follow-up 
observation by the end of a wave, the observation was ended at the midpoint of the prior 
observation and the cutoff point of the wave. Cutoff points were defined as follows: one 
week postpartum for wave 2; six weeks postpartum for wave 3; and 24 weeks 
postpartum for wave 4. For example, if a participant had a baseline interview during 
pregnancy (wave 1) but did not come to the follow-up interview between one week and 
five weeks postpartum (within wave 2), her first observation was terminated at the 
midpoint of the date of the wave 1 interview and one week postpartum.  
To test the effect of definition of the time point on the outcome, a second 
analysis was conducted in which regular cutoff points were applied to censored records 
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to estimate the time-to-event (alternative model). For example, if a participant who had 
a baseline interview during pregnancy (wave 1) but did not come to the follow-up 
interview between one week and five weeks postpartum, her first observation was 
terminated at one week postpartum. Her second observation was then started at one 
week postpartum. Sensitivity analysis was performed to test the effect of time definition 
on study outcomes by comparing results for censoring at the midpoint (main model) 
with the regular cutoff point (alternative model). 
Incidence of non-adherence was compared among 11 health facilities using a 
Log-rank test. The probability of remaining adherent among three facility types was 
calculated using survival function and was plotted with a Kaplan-Meier survival curve. 
The proportional hazards assumption was tested using log-log survival plot and 
Schoenfeld residuals. 
  The Cox multivariate regression model was tested to identify risk factors for 
non-adherence in a backward stepwise model-building procedure. The full model 
included all independent variables. The final model-building process treated 
independent variables in two groups: those regarded as essential in the study (age, 
education, marital status, health facility type, timing of HIV diagnosis), based on the 
reviewed literature and the context of study site (58, 59, 64, 67-72, 74), were retained 
regardless of significance; and other possible confounders were retained if their p-value 
was less than 0.05. It was not possible to run Cox proportional hazard regression using 
shared frailty and robust variance estimates simultaneously, so in these models the 
potential correlations within individuals were adjusted for using robust variance 
estimates, as they were considered likely to affect variance estimates more severely than 
the effect of facilities. Of all assessed models, the main model with essential and 
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significant covariates was adopted for discussing study findings.  Stata SE version 9.2 
(Stata Corp., TX) was used in all statistical analysis. 
 
2-9. Ethical considerations  
This study was approved by the Research Ethics Committee of the University of 
Tokyo (Appendix 8), and the Biomedical Research Ethics Committee of the University 
of Zambia (Appendix 9). At recruitment in the study, the study objective and protocol 
were explained to all mothers, and written informed consent was obtained from all of 
them. Face-to-face interviews were conducted in private rooms in health facilities. 
When interviewers found any problems in maternal and child health, medication and 
feeding practice, they provided counseling or referred the participant to health care 
workers for further support. Confidentiality of all collected data was strictly protected.
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3: Results 
3-1. Basic characteristics of mothers in the PMTCT program 
Table 1 shows the basic characteristics of 321 mothers. The referral health center 
enrolled 130 mothers (40.5%), the five PHCs with ART services enrolled 106 
(33.0%) mothers, and the five PHCs without ART services enrolled 85 mothers 
(26.5%). Half of the mothers (49.8%) were recruited in the study during pregnancy.  
The mean age of the mothers was 29.2 (SD 6.1) years old, 105 (32.7%) had 
education above primary level (8 years), and 272 (84.7%) were married or living 
with a partner. About half of mothers (49.5%) were newly diagnosed as HIV-
positive during the pregnancy. At baseline observation, 154 mothers (48.0%) were 
on ART, and 67 (20.9%) were non-adherent to ARV. One third (33.3%) had 
internalized-stigma, and 278 (86.6%) showed positive attitudes toward taking ARV. 
As for partner characteristics, 129 mothers (40.2%) had couple HIV testing and 
counseling with their partners, 258 (80.4%) had disclosed HIV status to their 
partners, and 134 mothers (41.7%) had HIV-positive partners, 52 partners (16.2%) 
were HIV negative, and 135 (42.1%) were of unknown status. Sixty-two mothers 
(19.3%) reported that they had recently experienced domestic violence. More than 
half of the mothers (58.3%) traveled more than 60 minutes to access the nearest 
health centers. Of these basic characteristics, educational level (p=0.01), marital 
status (p=0.04), timing of HIV diagnosis (p<0.01), timing of study enrolment 
(p=0.05), experience of couple HIV testing and counseling (p<0.01), HIV status of 
partner (p=0.03), and travel time to health facility (P<0.01) were significantly 
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different between referral health center, PHCs with ART services, and PHCs 
without ART services. 
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Table 1. Subject Characteristics (N=321).
Characteristics Overall p -value
N (%) 321 130 ( 40.5 ) 106 ( 33.0 ) 85 ( 26.5 )
Age
≤29 163 ( 50.8 ) 64 ( 49.2 ) 48 ( 45.3 ) 51 ( 60.0 ) 0.1
≥30 158 ( 49.2 ) 66 ( 50.8 ) 58 ( 54.7 ) 34 ( 40.0 )
Education level
≤Primary 216 ( 67.3 ) 76 ( 58.5 ) 81 ( 76.4 ) 59 ( 69.4 ) 0.01
≥Secondary 105 ( 32.7 ) 54 ( 41.5 ) 25 ( 23.6 ) 26 ( 30.6 )
Marital status
Not married 49 ( 15.3 ) 18 ( 13.9 ) 11 ( 10.4 ) 20 ( 23.5 ) 0.04
Married 272 ( 84.7 ) 112 ( 86.2 ) 95 ( 89.6 ) 65 ( 76.5 )
HIV diagnosis
Already diagnosed 162 ( 50.5 ) 68 ( 52.3 ) 68 ( 64.2 ) 26 ( 30.6 ) <0.01
Newly diagnosed 159 ( 49.5 ) 62 ( 47.7 ) 38 ( 35.9 ) 59 ( 69.4 )
ARV regimen
Prophylaxis 167 ( 52.0 ) 66 ( 50.8 ) 49 ( 46.2 ) 52 ( 61.2 ) 0.1
Treatment 154 ( 48.0 ) 64 ( 49.2 ) 57 ( 53.8 ) 33 ( 38.8 )
Study enrolment
During pregnancy 160 ( 49.8 ) 55 ( 42.3 ) 62 ( 58.5 ) 43 ( 50.6 ) 0.05
After delivery 161 ( 50.2 ) 75 ( 57.7 ) 44 ( 41.5 ) 42 ( 49.4 )
Baseline ARV adherence
Adherence 254 ( 79.1 ) 102 ( 78.5 ) 89 ( 84.0 ) 63 ( 74.1 ) 0.2
Non-adherence 67 ( 20.9 ) 28 ( 21.5 ) 17 ( 16.0 ) 22 ( 25.9 )
Internalized stigma
No 214 ( 66.7 ) 84 ( 64.6 ) 75 ( 70.8 ) 55 ( 64.7 ) 0.6
Yes 107 ( 33.3 ) 46 ( 35.4 ) 31 ( 29.3 ) 30 ( 35.3 )
Attitude on taking ARV
≤2 items agreed 43 ( 13.4 ) 16 ( 12.3 ) 16 ( 15.1 ) 11 ( 12.9 ) 0.8
3 items agreed 278 ( 86.6 ) 114 ( 87.7 ) 90 ( 84.9 ) 74 ( 87.1 )
Had couple HIV testing and counseling
No 192 ( 59.8 ) 97 ( 74.6 ) 46 ( 43.4 ) 49 ( 57.7 ) <0.01
Yes 129 ( 40.2 ) 33 ( 25.4 ) 60 ( 56.6 ) 36 ( 42.4 )
Disclosed HIV status to partner
No 63 ( 19.6 ) 21 ( 16.2 ) 18 ( 17.0 ) 24 ( 28.2 ) 0.07
Yes 258 ( 80.4 ) 109 ( 83.9 ) 88 ( 83.0 ) 61 ( 71.8 )
HIV status of partner
Negative 52 ( 16.2 ) 13 ( 10.0 ) 23 ( 21.7 ) 16 ( 18.8 ) 0.03
Positive 134 ( 41.7 ) 58 ( 44.6 ) 48 ( 45.3 ) 28 ( 32.9 )
Unknown 135 ( 42.1 ) 59 ( 45.4 ) 35 ( 33.0 ) 41 ( 48.2 )
Domestic violence
No 259 ( 80.7 ) 102 ( 78.5 ) 85 ( 80.2 ) 72 ( 84.7 ) 0.5
Yes 62 ( 19.3 ) 28 ( 21.5 ) 21 ( 19.8 ) 13 ( 15.3 )
Travel time to health facility (minutes)
≤59 134 ( 41.7 ) 84 ( 64.6 ) 21 ( 19.8 ) 29 ( 34.1 ) <0.01
≥60 187 ( 58.3 ) 46 ( 35.4 ) 85 ( 80.2 ) 56 ( 65.9 )
Note: Chi-square test.
Referral
Health
PHCs without
ART Service
Facility Type
PHCs with ART
Service
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3-2. Health facility profile 
Table 2 shows health facility profiles in 2011. The referral health facility provided 
antenatal and PMTCT services to the largest number of pregnant women and HIV-
positive pregnant women: an average of 19 pregnant women attended antenatal clinic, 
and four women were confirmed as HIV positive (including those who had already 
known their HIV-positive status before testing) and enrolled in the PMTCT program at 
weekly antenatal clinic. In PHCs, three to eight pregnant women attended the weekly 
antenatal clinic, and at most one of the women was found to be HIV-positive and 
enrolled in the PMTCT program.
  
Table 2. Health Facility Profile in 2011. 
Facility Number
a
1 2 3 4 5 6 7 8 9 10 11
Number of nurses in charge of Maternal and Child Health ward 7 2 1 1 2 3 1 1 1 2 1
Total number of new pregnant women attending the first antenatal clinic (ANC) 999 416 248 333 310 334 248 154 281 198 223
Total number of pregnant women confirmed as HIV positive 199 31 17 30 24 33 22 10 19 10 20
Average number of pregnant women attending the first ANC per week
b 19.2 8.0 4.8 6.4 6.0 6.4 4.8 3.0 5.4 3.8 4.3
Average number of pregnant women confirmed as HIV positive per week
c 3.8 0.6 0.3 0.6 0.5 0.6 0.4 0.2 0.4 0.2 0.4
a
1=referral health center; 2-6=primary health centers with ART service; 7-11=primary health centers without ART service.
b
Total number of pregnant women attending the first ANC was divided by total times of ANC opened within the year (52 times).
c
Total number of pregnant women confirmed as HIV positive was divided by total times of  ANC opened within the year (52 times).3
4
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3-3. Referral of new HIV-positive mothers to ART services  
Table 3 shows referral process of 159 mothers newly diagnosed as HIV-positive 
from the PMTCT program to ART clinics. Mothers attending the referral health center 
were more likely to have assessed CD4 count than mothers attending the PHCs (p<0.01). 
However, there were no significant differences in enrolment to ART clinic (p=0.4) and 
subsequent ART initiation (p=0.7) among the three types of health facility. 
 
 
Table 3. Referral to ART Service among Mothers Newly Diagnosed as HIV positive (N=159).
p -value
Newly diagnosed as HIV positive 62 38 59
Assessed CD4 count 55 ( 88.7 ) 20 ( 52.6 ) 26 ( 44.1 ) <0.01
Enrolled in ART clinic 26 ( 41.9 ) 21 ( 55.3 ) 30 ( 50.9 ) 0.4
Initiated ART by 6 months postpartum 16 ( 25.8 ) 8 ( 21.1 ) 17 ( 28.8 ) 0.7
Note: Chi-square test
N (%) N (%) N (%)
PHCs without
ART service
Facility Type
Referral
Health Center
PHCs with ART
service
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3-4. Incidence of non-adherence among health facility 
The Log-rank test demonstrated incidence of non-adherence was significantly 
different in the 11 facilities (p<0.01) (Table 4). The referral health center, three PHCs 
with ART services, and one PHC without ART services observed more non-adherence 
events than expected. 
 
Table 4. Incidence of non-Adherence among 11 Health Facilities.
Facility Number Subjects Observed Expected p -value
Incidence Incidence
1 130 189 147.8 <0.01
2 33 53 43.6
3 12 5 18.7
4 20 41 32.5
5 23 16 45.2
6 18 35 25.7
7 24 25 30.6
8 7 11 9.2
9 16 15 21.6
10 16 14 25.0
11 22 28 32.1
Note: Log-rank test
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3-5. Probability of remaining adherence by facility type 
Table 5 describes the probability of remaining adherent, in which midpoint was 
used for censorship, among the referral health center, five PHCs with ART services, and 
five PHCs without ART services. Overall probability of adherence in 11 facilities was 
0.54 (95% confidence interval (95% CI), 0.49-0.59), 0.30 (95% CI, 0.26-0.34), 0.19 
(95%CI, 0.16-0.23), and 0.12 (95% CI, 0.10-0.15) at 60 days, 120 days, 180 days, and 
240 days accordingly. In the same way, the probability of adherence was plotted using 
the Kaplan Meier survival method (Figure 2), which was significantly different in the 
three facility types (Log-rank test p<0.01).
  
3
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Table 5. Probability of Adherence by Health Facility Type.
Observation time Overall PHCs PHCs
(days) with ART service without ART service
Probability Probability Probability Probability
60 0.54 0.49 - 0.59 0.49 0.41 - 0.56 0.57 0.48 - 0.66 0.59 0.48 - 0.68
120 0.30 0.26 - 0.34 0.23 0.17 - 0.29 0.33 0.25 - 0.40 0.39 0.30 - 0.48
180 0.19 0.16 - 0.23 0.13 0.09 - 0.17 0.22 0.16 - 0.28 0.27 0.19 - 0.35
240 0.12 0.10 - 0.15 0.07 0.04 - 0.11 0.15 0.10 - 0.20 0.19 0.12 - 0.27
Note: Kaplan-Meier product limit methods.
Referral Health Center
95%CI 95%CI 95%CI 95%CI
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3-6. Evaluation of the proportional hazard assumption 
The proportional hazard assumption was evaluated using Schoenfeld residuals, 
which showed non-significance in a global test (p=0.8), although the domestic violence 
variable was significant (p=0.04) (Table 6). The log-minus-log survival curve for 
domestic violence was plotted, but it did not appear to seriously violate the proportional 
hazard assumption (Figure 3). Overall the model appeared to meet the proportional 
hazard assumption, and no further adjustments were deemed necessary. 
Figure 2. Probability of Adherence to ARV by Health Facility Type.
Note: Kaplan-Meier product limit methods.
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Table 6. The Proportional Hazard Assumptions of All Covariates.
rho p-value
Age -0.04 0.4
Education level 0.04 0.5
Marital status -0.05 0.3
Primary health centers with ART service 0.01 0.8
Primary health centers without ART service 0.00 1.0
HIV diagnosis 0.00 0.9
ARV regimen 0.05 0.4
Study enrolment -0.05 0.3
Baseline ARV adherence -0.01 0.9
Internalized stigma 0.02 0.6
Attitude on taking ARV 0.02 0.7
Had couple HIV testing and counseling -0.04 0.4
Disclosed HIV status to partner 0.02 0.6
HIV status of partner: Positive 0.02 0.7
HIV status of partner: Unknown 0.01 0.8
Domestic violence -0.10 0.04
Travel time to health facility -0.01 0.9
Global test 0.8
Note: Schoenfeld residuals. 
Figure 3. The Proportional Hazard Assumption of Domestic Violence.
Note: Log-minus-log survival plot.
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3-7. Risk factors for non-ARV adherence in the main model 
Table 7 indicates the risk factors for non-ARV adherence in the Cox 
proportional regression model. As the final model shows, mothers attending the PHCs 
with ART services (hazard ratio (HR: 0.71, 95% CI: 0.57-0.88) and mothers attending 
the PHCs without ART services (HR: 0.58, 95% CI: 0.46-0.74) were less likely to be 
non-adherent to ARV than mothers attending the referral health center. Mothers newly 
diagnosed as HIV-positive during pregnancy were more likely to be non-adherent than 
those who already knew their HIV status before pregnancy (HR: 1.24, 95% CI: 1.03-
1.50).  
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Table 7. Risk Factors for non-Adherence to ARV (Main Model)
a
.
Variables Full model
b
Final model
c
HR p-value HR p-value
Age
≤29 1.00 1.00
≥30 1.00 0.83 - 1.21 1.0 0.99 0.82 - 1.19 0.9
Education level
≤Primary 1.00 1.00
≥Secondary 0.95 0.77 - 1.17 0.6 0.91 0.75 - 1.11 0.4
Marital status
Not married 1.00 1.00
Married 0.92 0.67 - 1.27 0.6 0.97 0.75 - 1.25 0.8
Facility type
Referral health center 1.00 1.00
PHCs with ART service 0.72 0.56 - 0.92 <0.01 0.71 0.57 - 0.88 <0.01
PHCs without ART service 0.58 0.45 - 0.76 <0.01 0.58 0.46 - 0.74 <0.01
HIV diagnosis
Already diagnosed 1.00 1.00
Newly diagnosed 1.25 0.98 - 1.61 0.08 1.24 1.03 - 1.50 0.03
ARV regimen
Prophylaxis 1.00
Treatment 1.03 0.81 - 1.31 0.8
Study enrolment
During pregnancy 1.00
After delivery 1.12 0.90 - 1.39 0.3
Baseline ARV adherence
Adherence 1.00
Non-adherence 1.13 0.88 - 1.44 0.4
Internalized stigma
No 1.00
Yes 0.87 0.70 - 1.09 0.2
Attitude on taking ARV
≤2 items agreed 1.00
3 items agreed 0.90 0.68 - 1.19 0.5
Had couple HIV testing and counseling
No 1.00
Yes 1.10 0.85 - 1.41 0.5
Disclosed HIV status to partner
No 1.00
Yes 1.13 0.83 - 1.53 0.4
HIV status of partner
Negative 1.00
Positive 1.09 0.80 - 1.47 0.6
Unknown 1.23 0.89 - 1.70 0.2
Domestic violence
No 1.00
Yes 0.96 0.75 - 1.22 0.7
Travel time to health facility (minutes)
≤59 1.00
≥60 0.99 0.80 - 1.23 0.9
Note: Cox proportional hazard regression.
a 
Main model: Midpoints between two observations were used for censorship.
b
Full model: All covariates were included regardless of significant levels.
c
Final model: Age, education, marital status, facility type, HIV diagnosis, and covariates with significance were retained.
95% CI 95% CI
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3-8. Sensitivity analysis: effect of time definition 
This study utilized two models for censorship. The main model used midpoint 
between the date of the previous observation and the regular cutoff points of the current 
observation, and the alternative model used regular cutoff points. A comparison 
between the main model with all covariates (Table 7) and the alternative model with all 
covariates (Table 8) shows that health facility type was a significant predictor in both 
models. The hazard ratio for a new diagnosis of HIV during pregnancy was 1.25 (95% 
CI: 0.98-1.61) in the main model, whereas in the alternative model it was 1.13 (95% CI: 
0.92-1.38). For study enrolment after delivery, the hazard ratio in the main model was 
1.12 (95% CI: 0.90-1.39), while in the alternative model it was 1.40 (95% CI: 1.17-
1.67). Thus, sensitivity analysis indicated that time definition affected the confidence 
intervals, but did not make any changes in directions of the hazard ratios. 
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Table 8. Sensitivity Analysis (Alternative Model)
a
.
Variables Full model
b
Final model
c
HR p-value HR p-value
Age
≤29 1.00 1.00
≥30 0.99 0.85 - 1.15 0.9 0.99 0.85 - 1.15 0.9
Education level
≤Primary 1.00 1.00
≥Secondary 0.90 0.76 - 1.07 0.2 0.88 0.74 - 1.03 0.1
Marital status
Not married 1.00 1.00
Married 0.90 0.69 - 1.16 0.4 0.96 0.78 - 1.18 0.7
Facility type
Referral health center 1.00 1.00
PHCs with ART service 0.71 0.59 - 0.87 <0.01 0.73 0.62 - 0.86 <0.01
PHCs without ART service 0.69 0.55 - 0.86 <0.01 0.70 0.57 - 0.86 <0.01
HIV diagnosis
Already diagnosed 1.00 1.00
Newly diagnosed 1.13 0.92 - 1.38 0.2 1.09 0.93 - 1.28 0.3
ARV regimen
Prophylaxis 1.00
Treatment 1.03 0.85 - 1.25 0.8
Study enrolment
During pregnancy 1.00 1.00
After delivery 1.40 1.17 - 1.67 <0.01 1.40 1.17 - 1.68 <0.01
Baseline ARV adherence
Adherence 1.00
Non-adherence 1.05 0.88 - 1.26 0.6
Internalized stigma
No 1.00
Yes 0.92 0.77 - 1.09 0.3
Attitude on taking ARV 
≤2 items agreed 1.00
3 items agreed 0.93 0.76 - 1.13 0.5
Had couple HIV testing and counseling
No 1.00
Yes 1.07 0.88 - 1.30 0.5
Disclosed HIV status to partner
No 1.00
Yes 1.11 0.87 - 1.42 0.4
HIV status of partner
Negative 1.00
Positive 1.05 0.83 - 1.32 0.7
Unknown 1.10 0.85 - 1.42 0.5
Domestic violence
No 1.00
Yes 1.08 0.90 - 1.29 0.4
Travel time to health facility (minutes)
≤59 1.00
≥60 1.04 0.87 - 1.24 0.7
Note: Cox proportional hazard regression.
a 
Sensitivity analysis: Regular cutoff points were used for censorship.
b
Full model: All covariates were included regardless of significant levels.
c
Final model: Age, education, marital status, facility type, HIV diagnosis, and covariates with significance were retained.
95% CI 95% CI
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4: Discussion 
4-1. Summary of study findings 
This study examined ARV adherence of pregnant women and postnatal mothers 
until 24 weeks postpartum. Since the Zambian government revised the national PMTCT 
guidelines (based on Option A of the WHO 2010 guidelines), this study was the first 
operational evaluation on a longitudinal ARV adherence cohort controlling for the 
effect of loss to follow-up.  
The main finding to emerge was that maternal ARV adherence tremendously 
declined over the high-risk period for mother-to-child HIV transmission. Although no 
study has examined longitudinal ARV adherence under the WHO 2010 guidelines, a 
high incidence rate of non-ARV adherence has been consistently observed in various 
study settings and assessment periods (58-65, 82-84). As seriously high rates of loss to 
follow-up hindered optimal uptake of PMTCT programs in other African countries (23, 
85-88, 103), so they have also affected non-adherence of mothers in the present study. 
Maternal ARV adherence was affected by a health facility-specific effect: mothers 
attending secondary health facility showed poorer ARV adherence than those attending 
primary health facilities. At the individual level, the first diagnosis of HIV infection was 
a crucial risk factor for non-adherence.  
Toward eliminating HIV transmission, a universal “test and treat” strategy is one 
potential approach, based on providing therapeutic ART to all HIV-positive individuals 
soon after diagnosis (104). On the other hand, decentralization of ART services into 
primary care settings has seen a great impact on patients’ survival (105). Both 
approaches will be adopted in the new PMTCT program – namely, the Option B+ 
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regimen that provides for lifelong ART to all HIV-positive pregnant women (39, 106) 
(Appendix 2). The Option B+ regimen is expected to be advanced to Option A, as 
Option A assesses eligibility for ARV regimen based on CD4 counts, whereas most 
mothers in high HIV burden settings are not able to access CD4 testing facilities (107). 
The Zambian government has prepared for shifting from Option A to Option B+ at the 
policy level. Thus, before implementing Option B+, operational challenges should be 
discussed based on this study’s findings. 
 
4-2. Secondary health facility 
 ARV adherence among mothers attending the referral heath center was 
substantially poorer than in mothers attending the PHCs. This was affected by high 
incidence of loss to follow-up in referral health center. The poorer adherence in the 
referral health facility would attribute to maternal-specific factors or facility-specific 
factors specific, such as performance of health care providers, and availability of drugs 
and equipment (77, 108-110).  
Of the maternal basic characteristics, educational level, marital status, timing of 
HIV diagnosis, HIV status of partner, and travel time to health facility were different 
among health facility type. However, any characteristic other than timing of HIV 
diagnosis was not associated with non-adherence. Meanwhile, long distance to health 
facility, and mean and cost of transportation are major barriers to access and retain in 
the HIV care in the resource limited settings (111-113). In the central health facility, 
many patients come from remote areas, who would have an especially high risk of being 
non-adherent and being lost to follow-up – a common pattern observed at the hospital 
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(85, 112). Although travel time was not a risk factor in this study, it will be important to 
monitor mothers who come from remote area or who potentially transfer out of the 
referral health facility, and to link them to further PMTCT services.    
Health facility type was strongly associated with maternal adherence even after 
controlling for the basic characteristics of mothers. This suggests that facility-specific 
characteristics were independently associated with non-maternal adherence. The referral 
health center has an affiliated laboratory, daily ART clinic, and district pharmacy. Thus 
mothers attending the referral health center were less likely to experience running out of 
drugs, or repeated visiting for further clinical examination, compared with mothers 
attending PHCs. However, such benefits in the referral health center did not translate to 
better maternal adherence. 
The poor adherence observed in the secondary health facility might stem from 
the heavy workload placed on health care providers and the weak follow-up system for 
the PMTCT clients. For example, the referral health center opened its antenatal clinic 
once a week, and provided health check-ups, group pre-test HIV counseling, HIV 
testing, and individual post-test HIV counseling to about 20 pregnant women on the day. 
They then found about four HIV-positive pregnant women, dispensed ARV prophylaxis, 
and took blood samples for CD4 assessment until late afternoon. PHCs also provided 
the same antenatal care and PMTCT services once a week, but they had only three to 
eight pregnant women in a day, and found at most one HIV-positive pregnant woman. 
The large number of HIV-positive pregnant women attending the referral health center 
also made it difficult for staff and volunteers to identify mothers lost to follow up and 
trace them. In addition, the referral health center did not necessarily show better 
performance in provision of couples HIV testing and counseling, referral of PMTCT 
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clients to ART clinics, or subsequent ART initiation, compared with PHCs. This 
indicates that the referral health center had limited capacity to provide essential PMTCT 
interventions relative to the PHCs due to work burden on staff and volunteer workers.  
A study in South Africa reported that increased numbers of new HIV patients 
per health worker per year were associated with retention in ART services (114). This 
finding indicates that a higher patient load would detract from communicating with 
patients and supervising staff (114). This added workload could also limit health 
workers’ ability to provide sufficient counseling (114), leading to lower ARV 
adherence and treatment interruption. Because of staff shortages, mothers must wait for 
longer periods of time to receive services, which also affects increased loss to follow-
up (115).  To improve retention and adherence among mothers attending referral health 
facilities, potential strategies might be to accelerate decentralization of PMTCT and 
ART services and minimize the necessity of repeated visits for prescription refilling 
and health check-ups (85, 112).   
Implementation of the Option B+ regimen will promote decentralization of 
PMTCT services and reduce clients traveling from peripheral areas to the referral 
health center. However, staff and trained volunteers will also carry an additional 
workload in dispensing the therapeutic ARV regimen within the PMTCT program. 
Further task-shifting from clinicians to midwives and nurses, from midwives and nurses 
to trained volunteers would generate operational challenges. Through steps to careful 
task-shifting, training and allocating more staff and volunteers, and consistently 
supervising their performance should be considered (109, 116, 117). 
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4-3. Primary health facilities 
Mothers attending PHCs exhibited a better adherence than mothers attending the 
referral health center. In contrast to the referral health center, PHCs treated 10 to 30 
HIV-positive mothers within a year, which would enable them to provide better 
PMTCT services and prevent loss to follow-up and treatment interruption. During the 
observation period, trained TBAs who worked as interviewers for the present research 
were key players in connecting PMTCT services between health facilities and the 
community. They engaged in providing HIV testing, ARV prophylaxis, and adherence 
counseling at the health facilities, while also accompanying mothers to health facilities 
for delivery and advising them to receive postnatal ARV prophylaxis if mothers 
delivered at home. They also educated mothers on exclusive breastfeeding along with 
the benefits of taking ARV prophylaxis. However, these staff did not perform such 
function in the referral health center. 
Continuous support by trained volunteers beyond facility is beneficial for HIV-
positive mothers as they were a high-risk population for loss to follow-up and 
interruption of ARVs. In Malawi, trained community health workers have functioned as 
coordinators, improved retention, and increased utilization of PMTCT services (118). 
In addition, they can work for protect maternal and child health. A study in South 
Africa reported that 25% of child death was avoidable if family or community members 
detected sick children and referred them to health services effectively (119).  Although 
trained volunteers such as TBAs have complemented staff shortages in the PMTCT 
program in other parts of sub-Saharan Africa, standardizing their knowledge and skills 
through regular training and supervision, and evaluating their performance will be 
important to utilizing this workforce effectively for better PMTCT services (120-123).  
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 The Option B+ approach will be applied in Zambia from 2013. In accordance 
with the implementation of Option B+ in Malawi since 2011, all health facilities with 
antenatal clinic have integrated ART services into the PMTCT program (124). Within a 
year from introducing the Option B+, ART was successfully initiated among seven 
times more pregnant women and lactating mothers at a retention rate of 77% - a similar 
level to adults initiating ART during the period (124). An intervention study conducted 
in Zambia also reported that providing ART services at antenatal clinics increased the 
number of pregnant women who initiated ART before giving birth (125). In Zambia, 
however, only 25% of health facilities offered ART services for general HIV patients 
and 25% provided virological HIV testing to HIV-exposed children (42). Similarly, of 
the 19 PHCs in the study site, only five PHCs offered both PMTCT and ART services. 
Limited availability of ART services requires additional access to health facilities for 
HIV-positive mothers to continue lifelong ART.  Even though the more efficacious 
ARV regimen is provided in Option B+, such limited availability of ART services 
would increase the risk of loss to follow-up and treatment interruption. Thus, 
preparations should be made toward expanding ART services to all PHCs 
simultaneously. 
 
4-4. Newly diagnosed and ARV naïve mothers 
Mothers newly diagnosed as HIV-positive were at higher risk of non-adherence 
than mothers who already knew their HIV status before pregnancy. Several previous 
studies support this finding. In the United States, mothers initiating ART before 
pregnancy showed better adherence (59), two studies in sub-Saharan Africa also 
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reported that mothers on ART were more likely to administer sd-NVP to their infants 
within 72 hours (71), and less likely to miss ARV at labor and delivery (74).  
Opt-out HIV testing for pregnant women has made a great contribution to detect 
new HIV-positive women (22). However, few studies have discussed the risks for non-
adherence and attrition following the first diagnosis of HIV infection. In contrast to the 
mothers who already knew their HIV status, newly diagnosed HIV-positive mothers 
must deal with various novel issues after receiving HIV diagnosis, including the shock 
of diagnosis with a permanent and potentially fatal disease, disclosure of HIV status to 
their spouses, the new daily routine of medication, side-effects of ARV (e.g. AZT-
related anemia) (91), and the need for access to HIV care and treatment services. Poor 
physical and mental health and stigmatization are likely to make such issues more 
complicated (123).  
Universal HIV test and treatment before pregnancy can potentially improve 
PTMCT strategies by reducing the risk that pregnant women are not aware of their HIV 
status, thus it can reduce the number of women who suffer from complications 
attributed to new HIV diagnosis-related. This approach will be also beneficial to 
primary prevention among the reproductive aged population, which is highlighted as 
one of the four targets in the PMTCT program (21). Despite the high HIV prevalence in 
the study site, half of the participant mothers did not notice their HIV-positive status 
until antenatal HIV testing, and 40% of their partners remained of unknown status. This 
is a common situation across the country, in which about 70% of HIV-positive men and 
50% of HIV-positive women had never been tested before their first HIV-positive 
diagnosis (48). Thus, improving the rate of testing in the community and encouraging 
regular testing among all sexually active young people will likely have subsidiary 
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benefits for PMTCT strategies, as it will reduce the number of women who are 
unprepared for initiation of ARV in pregnancy. PHCs and other health agencies in 
Zambia should redouble their efforts to encourage HIV testing in the general population, 
and novel approaches should be found to encourage those considering starting a family, 
or those in stable sexual relationships, to obtain regular HIV testing. Additionally, cost-
effectiveness of this strategy should be evaluated, as it requires considerable financial 
investment and human resource (126). 
Corresponding to HIV testing before pregnancy approach, couple testing and 
counseling will be also an effective intervention to improve adherence of mothers newly 
diagnosed as HIV positive. Previous studies have demonstrated its multiple effects, such 
as promoting disclosure of HIV status among couples (47, 127), reducing loss to follow-
up (80), increasing provision of ARV prophylaxis (128) and administration of ARV 
(129, 130) with no association with domestic violence and abuse attributed to disclosing 
HIV status to partner (95). Thus, couple HIV testing and counseling will provide 
various benefits to improve uptake of PMTCT program in women newly diagnosed as 
HIV-positive and their partners. However, only 40% of the study participants have 
taken couple HIV testing and counseling. A future research should focus on individual- 
and facility-specific barriers to expand the couple HIV testing and counseling service in 
the study site. 
Further efforts for enrolment in the ART clinic is also needed to improve 
adherence in newly diagnosed HIV-positive mothers. As previous studies reported, 
better adherence of mothers already on ART was a consequence of longer experience of 
medication and improved health status by taking ARV, stronger risk perception for the 
disease, and increased opportunities for adherence support (59, 71). In contrast, newly 
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diagnosed HIV-positive mothers are ARV naïve and have less directly experienced 
HIV-related symptoms (131). Lack of information on ART services and negative 
perception on ARV drugs were also barriers to start or continue ART (132). Initially, 
HIV-positive mothers have a strong intention to protect and take care of their children, 
and such motivation facilitates their adherence (84, 133, 134). Despite this, 30% of 
maternal death was caused by HIV-related disease in 2010 in Zambia (135). Thus, it is 
crucial to develop knowledge of health risks and available health services to establish 
better compliance with prescribed drugs (136-138). ART clinics play a crucial role in 
providing such information through clinical examination, treatment, and adherence 
counseling that cannot be covered in the PMTCT program. Although the primary 
determinant of whether HIV-positive mothers access HIV treatment is their personal 
health-seeking behavior, the PMTCT program needs to make further effort to ensure 
referrals of the mothers to ART clinics. 
 
4-5. Limitations 
Although this study yielded novel findings toward improving the PMTCT 
services in Zambia and comparable settings, it has several limitations. First, this study 
used a single measurement of self-reported ARV adherence. Any self-reported 
measurement is potentially affected by recall bias and social desirability bias. However, a 
four day self-report adherence instruments asked the latest adherence, to maximize 
recall while minimize bias (92). Thus it was unlikely to be much affected by recall bias. 
Second, this study might overestimate incidence of non-adherence because all 
subjects who did not attend scheduled interviews were treated as non-adherent. 
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However, it would be rational to consider that mothers missed the scheduled visits were 
likely to be non-adherence to medication (100). In addition, this is an operational 
research using intention-to-treat analysis, designed to observe the standard practice of 
the PMTCT program and give conservative results. It would be worthwhile to conduct 
an intervention study to trace mothers who missed interviews and who were lost to 
follow up, and investigate their reasons and ARV adherence while lost to follow-up.  
Third, detailed information on facility characteristics was not collected in the 
study, although health facility type was a predictor for adherence. Further study is 
warranted to collect additional data about facility-specific characteristics that would 
facilitate or hinder adherence with the PMTCT program. 
Despite these limitations, the study constitutes a significant contribution to the 
field in operating the 2010 PMTCT guidelines, as it identified risk factors for ARV non-
adherence in a longitudinal cohort, controlling for the effects of loss to follow-up that 
have seriously undermined the program outcomes. Based on the findings, potential 
operational challenges toward implementing the advanced protocol of Option B+ were 
indicated.
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5: Conclusions and Recommendations 
 This is the first prospective cohort study that assessed ARV adherence in the 
PMTCT program since the Zambian government introduced an extended prophylaxis 
regimen based on WHO 2010 guidelines. High incidence of non-adherence was 
observed by controlling for the effect of loss to follow-up. 
 Mothers attending a referral health center showed poorer adherence than 
mothers attending PHCs. The Zambian government plans to adopt the Option B+ 
regimen, which offers lifelong ART to all HIV-positive pregnant women and postnatal 
mothers. Based on the study findings, several interventions are recommended to operate 
the Option B+ effectively. In the referral health center, the Option B+ regimen will 
increase staff workload due to treating the largest number of PMTCT clients. This will 
further affect maternal retention and adherence in the PMTCT program. Although a 
future goal should be to provide PMTCT services by skilled health workers, increasing 
trained TBAs and careful task-shifting, and continuous follow-up beyond health facility 
are crucial responses to improve the quality of the services and retention of clients in the 
referral health center. In the PHCs, on the other hand, general ART services should be 
expanded to all sites in conjunction with the PMTCT program. Otherwise, loss to 
follow-up and treatment interruption will undermine the program outcome.  
 New HIV diagnosis during pregnancy was a significant risk factor for non-
adherence due to multiple issues following the HIV diagnosis. Opt-out antenatal HIV 
testing is an effective intervention to detect new HIV cases in pregnant women. 
However, expanding HIV testing and treatment before pregnancy will also help women 
to overcome multiple barriers to medication in advance, and to improve their adherence 
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and retention in the program. In addition, scale up of couple HIV testing and counseling, 
and integrated ART services in the PMTCT program will be also beneficial for mothers 
newly diagnosed as HIV-positive to improve their adherence. Health centers, 
international organizations operating in Zambia, and the Zambian health authorities 
should redouble their efforts to improve testing rates among sexually active young 
people and to encourage regular testing even among women in stable relationships. 
Such a program will have benefits not only in general HIV prevention, but in improving 
the effectiveness of PMTCT programs through reducing the number of women entering 
antenatal care who are naïve to their own HIV status. 
Towards eliminating mother-to-child transmission of HIV and keeping HIV-
positive mothers survival longer, not only prescribing efficacious ARV regimen, but 
comprehensive services to reduce loss to follow-up and improve adherence is necessary, 
considering both facility- and individual-specific factors. Simultaneously, cost-
effectiveness in the PMTCT program should be taken into account as it requires huge 
financial investment. Through such tactics, Zambia can improve both the health of 
pregnant women with HIV and their babies, and also minimize the risk of HIV 
transmission to a new generation, and make a significant contribution to the long-term 
eradication of this epidemic. 
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Appendices 
  
Appendix 1. Major Revisions in the WHO Guidelines from 2006 to 2010 Option A.
2006 guidelines 2010 guidelines
[1] ARV eligibility criteria
▶Clinical stage 1-2 with CD4 < 200 cells/mm
3
▶CD4 ≤ 350 cells/mm
3
,
▶Clinical stage 4, irrespective of CD4 cell count  irrespective of clinical stage
▶Clinical stage 3, with CD4 < 350 cells/mm
3 ▶Clinical stage 3-4,
irrespective of CD4 cell count
[2] Timing to start ARV prophylaxis
▶From 28 weeks of gestation ▶As early as 14 weeks of gestation
[3] Prophylaxis regimen for HIV-exposed infants
(i) Infants born to mothers on ART
▶zidovudine (AZT) for 7 days ▶nevirapine (NVP) or AZT for 4-6 weeks
(ii-a) Breastfeeding infants born to mothers not on ART
▶single-dose NVP + AZT for 7 days
(ii-b) Non-breastfeeding infants born to mothers not on ART
▶single-dose NVP + AZT for 7 days NVP or single-dose NVP + AZT for 4-6 weeks
Modified from Antiretroviral drugs for treating pregnant women and preventing HIV infections in infants:
recommendations for a public health approach 2010 version (WHO).
NVP from birth to until 1 week after complete cessation
of breastfeeding
  
  
Appendix2. Three Options of WHO PMTCT Guidelines.
Mother: Treatment Mother: Prophylaxis Infant
Option A Antepartum : AZT
a
 starting
from 14 weeks of gestation
Intrapartum : At onset of
labor, single-dose NVP
b
 and
AZT/3TC
c
 administering
Option B
Option B+
Modified from Programmatic update: use of antiretroviral drugs for treating pregnant women 
and preventing HIV infection in infants executive summary (WHO).
a
zidovudine, 
b
nevirapine, 
c
lamivudine.
(CD4 count ≤ 350
cells/mm
3
)
(CD4 count > 350
cells/mm
3
)
Postpartum : Daily
AZT/3TC for 7 days
postpartum taking
Triple ARVs starting from
14 weeks of pregnancy and
continued until delivery if
infant not on breastfeeding;
or continued by mother until
1 week after complete
cessation of breastfeeding
All infants take daily NVP
or AZT from birth to 4-6
weeks
Triple ARVs starting as
soon as diagnosis, continued
for a lifelong
If infant on breast feeding,
daily NVP from birth to 1
weeks after complete
cessation of breastfeeding;
or if infant not on
breastfeeding or if mother
on ART, daily NVP from
birth to 4-6 weeks
Triple ARVs initiation
soon after diagnosis, and
continued for a lifelong.
Triple ARVs starting
soon after HIV
diagnosis, and continued
for a lifelong
All infants ingest daily NVP
or AZT from birth to 4-6
weeks
Triple ARVs starting as
soon as diagnosis,
continued for a lifelong
  
 
  
Appendix 3. 2010 Zambia National Protocol Guidelines
Modified from 2010 National Protocol Guidelines. (Ministry of Health, Republic of Zambia) 
Establish HIV status of 
pregnant women
Start ART Maternal Zidovudine (AZT) prophylaxis 
starting from 14 weeks gestation
Not eligible for ART;
Requires ARV prophylaxis
Eligible for ART
Retest after 3 months or 
in 3rd trimester
HIV test negative
Determine ART 
eligibility 
HIV test positive
Continue ART           
Known HIV infection
and already on ART
Continue ART
Single-dose nevirapine (sd-NVP)
at the start of labour 
and AZT and lamivudine (3TC)
Breastfeeding
Mothers: Continue AZT+3TC 
until 1 week after delivery
Infants: Daily NVP from birth 
until 1 week after all exposure 
to breast milk has ended, or if 
breastfeeding stops before 
6 weeks, for a minimum of 
6 weeks following birth.
Breastfeeding or 
replacement feeding
Mothers: Continue ART
Infants: Daily NVP from birth 
until 6 weeks of  age
Replacement feeding only
Mothers: Continue AZT+3TC
until 1 weeks after delivery
Infants: Daily NVP from birth 
to 6 weeks of  age
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Appendix 4. Literature Review on Risk Factors of non-Adherence.
Study Year Country Stage / Subject Adherence Risk factor
[1] High-income country
Laine
(59)† 2000 USA antenatal 34%
Wilson
(60) 2001 USA antenatal 80% illicit drug use, missed prenatal vitamin
Demas
(61) 2002 USA neonatal 71%
Ickovics
(62) 2002 USA antenatal 50%
‡ administered >2 times/day
postnatal 34%
‡
Demas
(63) 2005 USA antenatal 68%
Bardeguez
(64) 2008 USA antenatal 75%
postnatal 64-66%
Mellins
(65) 2008 USA antenatal 61%
postnatal 44%
[2] Sub-Saharan Africa, intrapartum nevirapine regimen
Stringer
(78) 2003 Zambia mother 61%
(intervention)
mother 74%
(control)
Stringer
(66) 2005 Zambia mother 68%
infant 90%
Albrecht
(67) 2006 Zambia mother 94%
infant 91%
Karcher
(68) 2006 Tanzania mother 42%
infant 44%
Uganda mother 46%
infant 24%
Bii
(69) 2007 Kenya mother 90%
infant 91%
Kasenga
(76) 2007 Malawi mother 75% home delivery
infant 52%
Chi
(79) 2008 Zambia mother 54% (not reported)
intervention arm (offered NVP without
HIV testing), illiteracy, non experience of
prior fetal or infant death
longer interval between HIV test and
delivery
home delivery, no high school education,
low newborn birth weight
hospital delivery, low apgar score, infant
death within 28 days of age
self-administered NVP at home, age<25,
non-secondary education, non-Catholic
religion, not had PMTCT counseling at
hospital
not used ART before pregnancy,
ethnicity(Black, Hispanic), age<20,
residence area (New York)
not disclosed HIV status, not participated
in support group
used ART before pregnancy, had AIDS,
missed prenatal vitamin, used marijuana,
not felt happy
poor social support network, not disclosed
HIV status, poor antenatal adherence,
asymptomatic status, have >2 children
antenatal attendance<2, age<20, single
woman, home delivery, maternal poor
adherence
higher viral load, HIV symptoms,  clinic
attendance>6 times, alcohol consumption
  
  
Delvaux
(70) 2009 Rwanda mother-infant 53%
Barigye
(71) 2010 Uganda mother 60%
infant 43%
Conkling
(80) 2010 Zambia mother 79% (no significant factor)
Rwanda mother 88%
Kuonza
(72) 2010 Zimbabwe mother 69%
infant 73%
Megazzini
(81) 2010 Zambia mother-infant 52%
(intervention)
mother-infant 43%
(control)
Peltzer
(73) 2010 South Africa mother 78%
infant 77%
Stringer
(74) 2010 Cameroon mother 85%
Cote d'Ivoire 69%
South Africa 82%
Zambia 79%
Mirkuzie
(75) 2011 Ethiopia mother 60% home delivery
infant 87%
[3] Sub-Saharan Africa, ARV prophylaxis regimen
Chung
(57) 2008 Kenya antenatal-postnatal 96%
‡ not reported
Kirsten
(58) 2011 Tanzania antenatal 50%
intrapartum mother 42%
postnatal infant 19%
Peltzer
(82) 2011 South Africa antenatal 61%
postnatal 86%
Mepham
(83) 2011 South Africa antenatal-postnatal 61%
Ekama
(84) 2012 Nigeria antenatal 81%
† reference number
‡ mean level of adherence
not disclose HIV status, not have
treatment partner
qualitative answer: misunderstood
therapy, domestic violence, poverty, not
disclosed HIV status, stigma
control arm (vs. intervention arm: offered
HIV test after HIV test and NVP
adherence assessment at labor ward)
age<30, gravidity>4, antenatal
attendance<6, vaginal delivery, single
dose NVP regimen (vs. ART)
age<24, no income generating activity,
enrolled in PMTCT<24week, not
disclosed HIV status
not disclosed HIV status, discrimination,
poor partner involvement
poor knowledge of PMTCT, not
disclosed HIV status, premature delivery,
not told partner about HIV test or ARV,
not knew infant's HIV status
not experienced PMTCT program, not
prescribed NVP in advance, no
secondary education, multi-parity, home
delivery, not disclosed HIV status
residence area (not study site), first
antenatal attendance at early pregnancy,
preferred to receiving NVP at facility,
24<age>35, not on ART
unmarried, education<3 years, antenatal
attendance <2, offered HIV test after
first antenatal attendance, not disclosed
HIV status
  
 
Appendix 5. Maps of Study Site.
Chongwe 
District
  
  
Appendix 6. Survey Tools
1 Research ID 
* Facility code 04. Chinyunyu 08. Chitemalesa
01. Chongwe 05. Kasisi 09. Kampekete
02. Kanakantapa 06. Lwiimba 10. Mpango
03. Chalimbana 07. Chainda 11. Nyangwena
2 Date of Enrolment (DD/MM/YYYY)
3 Safe Motherhood No.
4 Under five No.
*If twin, under five No. of the second baby 
5 Name of ART clinic
6 Age 
Participant's Date of Birth
7  (DD/MM/YYYY)
Baby's Date of Birth 
8 (DD/MM/YYYY)
9 Language of the interview
English Nyanja Bemba Tonga Other ( )
0 1 2 3 4
1.Basic Information 
  
  
Research ID
1 Antenatal Details (1:Antenatal Card, 2:Safe motherhood Register, 3:Integrated Counselling Register)
1 Date of 1st antenatal visit (2-a) (dd/mm/yyyy) No Record
2 Last menstruation period [LMP](2-i) (dd/mm/yyyy) No Record
3 Gestation in week at 1st ANC(2-k) weeks No Record
4 Estimated delivery date [EDD](2-j) (dd/mm/yyyy) No Record
5 Gravida (2-g) times No Record
6 Parity (2-h) times No Record
7 Syphilis test (2-s.t) RPR 1 Reactive 1 Negative 0 No Record
RPR 2 Reactive 1 Negative 0 No Record
8 Syphilis treatment (2) Treated 1 Not treated 0 No Record
9 Total number of ANC visits (2-a) times No Record
10 Partner took HIV test (3-i) Tested Yes 1 No 0 No Record
Date (dd/mm/yyyy) No Record
Result Positive 1 Negative 0 No Record
2 Delivery Details (1:Antenatal Card, 2:Delivery Register, 3:MTCT Labour Ward Register)
1 Date of Delivery (1, 2 or 3) Date(dd/mm/yyyy) No Record
Gestation ( ) week No Record
2 Outcome of delivery (3-o) Alive 1 Died 0 No Record
3 Apgar score (2-ad) (　　　　　　)　/ (10 scores) No Record
4 Birth weight (2-ae) (          ) days of age (          ) kg No Record
5 Sex of baby (2-ag) Female 1 Male 0 No Record
6 Place of delivery (2) Home 1
Facility( ) 2
Other( ) 3
7 Mode of Delivery [MoD] (2-u) Vaginal 1 Caesarean 0 No Record
8 Place NVP was taken at labour (3-k&l) Did not take 0
Took at Home 1
Took at Facility 2
9 Intrapartum AZT & 3TC (3-m) Taken ☐ 1 Not taken 0 On ART No Record
10 7 days Postnatal AZT& 3TC to mother Given ☐ 1 Not given 0 On ART No Record
11 ARV prophylaxis to Baby (3-n) Given ☐ 1 Not given 0 No Record
No Record
No Record
2.Register  Data 
On ART
  
  
Research ID
3 Postnatal Details (1:Children under 5 card, 2:Children under 5 register)
1 Date of 6 days visit (dd/mm/yyyy) No visit No Record
2 Date of 6 weeks visit (dd/mm/yyyy) No visit No Record
3 Immunization 1) BCG (2-g) Given 1 Not given 0 No Record
2) BCG scar (2-h) Given 1 Not given 0 No Record
3) DPT/HepB/Hib-1(2-i) Given 1 Not given 0 No Record
4) DPT/HepB/Hib-2(2-j) Given 1 Not given 0 No Record
5) DPT/HepB/Hib-3(2-k) Given 1 Not given 0 No Record
6) OPV-0 (2-l) Given 1 Not given 0 No Record
7) OPV-1(2-m) Given 1 Not given 0 No Record
8) OPV-2(2-n) Given 1 Not given 0 No Record
9) OPV-3(2-o) Given 1 Not given 0 No Record
10) OPV-4(2-p) Given 1 Not given 0 No Record
11) Measles (2-q) Given 1 Not given 0 No Record
4 Vitamin A supplement 1st (2-aa) Given 1 Not given 0 No Record
2nd(2-ag) Given 1 Not given 0 No Record
3rd(2-ak) Given 1 Not given 0 No Record
4 Mother ARV Prophylaxis/ ART Details (1:Integrated Counselling Register, 2:ART patient file, 3:SmartCare)
1 Date of HIV diagnosis(1-B or L, 2 or 3) (dd/mm/yyyy) No Record
2 Date of Prophylaxis AZT initiated (1-remarks) (dd/mm/yyyy) No Record
3 Date of Cotrimoxazole initiated (1-remarks) (dd/mm/yyyy) No Record
4 Date of referral to ART clinic (1-q) (dd/mm/yyyy) No Record
5 Date of enrolment in Pre-ART clinic(2or3) (dd/mm/yyyy) No Record
6 Pre-ART Number(2or3)
7 Date of enrolment in ART clinic(2or3) (dd/mm/yyyy) No Record
8 ART Number(2or3)
9 Date of HAART initiated(2or3) (dd/mm/yyyy) No Record
No Record
No Record
2.Register  Data 
  
Research ID
5 Infant ARV Prophylaxis/ ART Details  (1:Baby Mother Follow up Register, 2:ART patient file, 3:SmartCare)
1 Date of Prophylaxis NVP initiated(1-u) (dd/mm/yyyy) No Record
2 Date of Cotrimoxazole initiated(1-u) (dd/mm/yyyy) No Record
3 Date of HIV diagnosis(1-s,t, ad,ae) (dd/mm/yyyy) No Record
4 Date of referral to ART clinic (dd/mm/yyyy) No Record
5 Date of enrolment in ART clinic(2or3) (dd/mm/yyyy) No Record
6 ART Number (2or3)
7 Date of HAART initiated(2or3) (dd/mm/yyyy) No Record
6 Survival Status: If mother or baby die or terminated the current pregnancy (abortion), 
record below and consultant DHO for continuation of study.
1 Date of Mother's death (dd/mm/yyyy) No Record
2 Cause of Mother's death No Record
3 Date of Baby's death (dd/mm/yyyy) No Record
4 Cause of Baby's death No Record
5 Date of Abortion (terminated pregnancy) (dd/mm/yyyy) No Record
6 Cause of Abortion Induced 1 Natural 0 No Record
No Record
2.Register  Data 
  
  
Research ID
7 Mother PMTCT follow up
* If there is no record, please write 
   "NR" in the blank.
1 Height (cm)
2 Weight (kg)
at enro lment
3 Haemoglobin (mg/dl)
4 WHO clinical stage 
5 CD4 assessment Date(dd/mm/yyyy)
CD4 count
6 Eligibility for ART Yes 1 No 0 Yes 1 No 0 Yes 1 No 0 Yes 1 No 0 Yes 1 No 0 Yes 1 No 0
7 ARV regimen Name of Drug1
Name of Drug2
Name of Drug3
8 ART refill visits in the last 6 months
12 months after
delivery
18 months after
delivery
Antenatal period 6 days after delivery
6 weeks after
delivery
6 months after
delivery
2.Register Data 
  
Mother's Research ID
8 Baby PMTCT follow up
* If there is no record, please write 
   "NR" in the blank.
1 Opts for Exclusive Breast feeding(EBF) EBF 1 No 0 EBF 1 No 0 EBF 1 No 0 EBF 1 No 0 EBF 1 No 0
2 HIV test Date(dd/mm/yyyy)
6wk, 6mo=DBS Result R  1 NR  0 R  1 NR  0 R  1 NR  0 R  1 NR  0 R  1 NR  0
12m,18m=Rapid Test R= Reactive, NR=Non Reactive
3 Height (cm)
4 Weight (kg)
5 Haemoglobin (mg/dl)
6 WHO clinical stage 
7 CD4 assessment Date(dd/mm/yyyy)
CD4 Count
CD4 (%) % % % % %
8 Eligibility for ART Yes 1 No 0 Yes 1 No 0 Yes 1 No 0 Yes 1 No 0 Yes 1 No 0
9 ARV regimen Name of Drug1
Name of Drug2
Name of Drug3
10 ART refill visits in the last 6 months
Indeterminate ☐  2
18 months after
delivery
Indeterminate ☐  2 Indeterminate ☐  2 Indeterminate ☐  2 Indeterminate ☐  2
2.Register Data 
6 days after delivery
6 weeks after
delivery
6 months after
delivery
12 months after
delivery
  
 
  
1 Research ID 
* Facility code 04. Chinyunyu 08. Chitemalesa
01. Chongwe 05. Kasisi 09. Kampekete
02. Kanakantapa 06. Lwiimba 10. Mpango
03. Chalimbana 07. Chainda 11. Nyangwena
2 Date of Interview (DD/MM/YYYY)
3 Safe Motherhood No.
S. Confirmation of Study Participant:
 Let us confirm whether you are eligible for joining the study.
S002. Did you already known your HIV positive status
before the present pregnancy?
Before the pregnancy 1
During or After the pregnancy 0 →  Go to A009
S003. Are you already on lifelong treatment for HIV Yes 1
(ART/HAART) before the present pregnancy ? No 0 →  Go to A009
S004. If you are on lifelong treatment (ART), 
when did you start ART? (dd/mm/yyyy)
S005. Do you visit the same health centre for antenatal clinic and ART clinic?
Same 1 →  Go to A009
Different 0
N/A 99 →  Go to A009
S006. Name of health facility for ART clinic : 
A. Socio-demographic Characteristics:  
 Please answer about your social background.
A009. Age years old
A010. Religion Christian Muslim Other Nothing
1 2 3 0
A011. Education level None 0
[the last grade achieved] Highest Grade(1-12) (               ) ←Write Grade
College/University 13
3) Basic Information, and 4) Register Data sheet.
 Before starting, fill in 1) Participant List, 2) Appointment card
Enrolment
  
  
A012. Education level of your partner None 0
[the last grade achieved] Highest Grade(1-12) (               ) ←Write Grade
College/University 13
If no partner, N/A 98
Don't know 99
A013. Number of family members living together 
including yourself Adults
Children (age <18)
A014. Does anyone in your household own agricultural field?
Yes 1 No 0
A015. Do you have the following things in your house?
 (Ask one by one) 1) Tap water Yes 1 No 0
2) Electricity Yes 1 No 0
3) Gas/Electricity for cook Yes 1 No 0
4) Television Yes 1 No 0
5) Radio Yes 1 No 0
6) Mobile phone Yes 1 No 0
Please answer about access to the health centre.
A016. How did you come here today?
1) On foot 1
2) Bicycle 2
3) Motor bike 3
4) Mini bus 4
5) Other ( )
A017. How long do you take to travel back
 to your home? (One way) hours minutes
A018. How much does it cost you for travelling
 back to your home? 
   One way by means answered in A016. Kwacha
   Ex) If on foot, write Zero.
A019. Is this health centre the closest one to your home?
Yes 1 No 0
M. Family Planning:
Please answer about various ways or methods that 
a couple can use to delay or avoid a pregnancy.
M001. Do you want to have more children? No 0
Yes 1
Declined to answer 99
M007. Is the current pregnancy/baby planned one? No 0
Yes 1 →  Go to another
Declined to answer 99      questionnaire.
  
  
M003. Did you use any methods to delay or avoid this pregnancy?
No 0
Yes 1 →  Go to another
Declined to answer 99      questionnaire.
M005. If No , why didn't you use any method to delay or avoid a pregnancy (=FP)?
 (Ask one by one)
1) You didn't know any FP method. Yes 1 No 0
2) You did not know where you can get a FP method. Yes 1 No 0
3) You did not ask health worker for a FP method. Yes 1 No 0
4) Your religion did not allow to use a FP method. Yes 1 No 0      Go to another
5) You were afraid of health problems (side-effect). Yes 1 No 0          questionnaire.
6) You did not want to use a FP method. Yes 1 No 0
7) Your partner did not want to use a FP method. Yes 1 No 0
8) You used a traditional method instead. Yes 1 No 0
9) You are breastfeeding. Yes 1 No 0
10) Other : Specify ( )
  
  
1 Research ID 
* Facility code 04. Chinyunyu 08. Chitemalesa
01. Chongwe 05. Kasisi 09. Kampekete
02. Kanakantapa 06. Lwiimba 10. Mpango
03. Chalimbana 07. Chainda 11. Nyangwena
2 Date of Interview (DD/MM/YYYY)
3 Safe Motherhood No.
4 Age of Baby ( )weeks
☆Confirmation of enrolment
Is this her first interview for this study? Yes 1 → fill in 1) Participant list
No 0 2) Appointment card
3) Basic Information
4) Register Data
5) ART information sheet
6) Enrolment sheet
A. Socio-demographic Characteristics:  
 Please answer about your social background.
A401. Marital status Married 0
Living with a man 1
Divorced/Separated 2
Widowed 3
Never Married 4
A402. Estimated household income per month <50,000 0
(Kwacha) 50,000-99,999 1
100,000-199,999 2
200,000-499,999 3
>500,000 4
Declined to answer 99
A403. Do you usually work? No 0
(Only for paid work) Once in a while 1
Part of the year 2
Throughout the year 3
A404. Does your partner usually work? No 0
(Only for paid work) Once in a while 1
Part of the year 2
Throughout the year 3
If no partner,  N/A 98
  
  
A405. During the past month, how often have you Never 0
had problems getting the food you need? Sometimes 1
Always 2
A406. During the past month, how often have you Never 0
had a drink containing alcohol? Once a Month 1
2 or 3 Times a Month 2
Once or Twice a Week 3
3 or 4 Times a Week 4
5 or 6 Times a Week 5
Daily 6
A407. Do you currently smoke cigarettes? Yes 1
No 0
A408. Did you change your residence since the last interview? Yes 1
No 0
This is the first interview, NA. 98
B. General Health:
 Please answer about your health condition.
B401. In general, would you say your health is: Poor 0
Fair 1
Good 2
Excellent 3
B402. Have you ever had any problems (side-effects) Yes 1
since starting medications for HIV (ARV)? No 0
B403. In general, would you say your baby's health is: Poor 0
Fair 1
Good 2
Excellent 3
B404. Recent body weight of the baby kg (age by WEEK)
B405. Has your baby  ever had any problems (side-effects)
since starting medications for HIV (ARV)? Yes 1
No 0
If baby has never taken medication for HIV, N/A 98
C. Mental Health: 
C401. Please describe how often you felt or behaved this way
 during the past week.
- Rarely or none of the time (less than 1 day)
- Some or a little of the time (1-2 days) Less than 1 to 2 3 to 4 5 to 7 
- Occasionally or moderate amount of time (3-4 days) 1 day days days days
- Most or all of the time (5-7 days) Rare or Some or Occasionally Most or
None a little or Moderate All
1) Were you bothered by things that usually don't bother you? 0 1 2 3
2) Did you have trouble keeping your mind on what you were doing? 0 1 2 3
3) Did you feel depressed? 0 1 2 3
  
  
- Rarely or none of the time (less than 1 day) Less than 1 to 2 3 to 4 5 to 7 
- Some or a little of the time (1-2 days) 1 day days days days
- Occasionally or moderate amount of time (3-4 days) Rare or Some or Occasionally Most or
- Most or all of the time (5-7 days) None a little or Moderate All
4) Did you feel that everything you did was an effort? 0 1 2 3
(Did you feel like you were too tired to do things?)
5)*  Did you feel hopeful about the future? 3 2 1 0
 (reverse)
6) Did you feel fearful? 0 1 2 3
7) Was your sleep restless? 0 1 2 3
8)* Were you happy? 3 2 1 0
 (reverse)
9) Did you feel lonely? 0 1 2 3
10) Could you not get 'going'? 0 1 2 3
(Was it hard to get started doing things?)
D. Internalized Stigma:
 Please answer about how you feel or behave due to your HIV status
D402. Do you sometimes feel bad about yourself Disagree 0
because you are HIV-positive? Unsure 1
Agree 2
Declined to answer 99
E. Partner/ Family:  
Please answer about attitudes of your partner & family members to you
"Family member" includes those who lives together
E401. Do you live with your partner or adult family members? Yes 1
No 0 →  Go to "F".
E402. Since this pregnancy , did your partner take Yes 1
a couple counselling and testing for HIV? No 0
Declined to answer 99
E403. What is your partner's HIV status? Positive 1
Negative 0
Unsure 2           Go to E405.
Declined to answer 99
E404. Does your partner take medication for HIV (ARV)? Yes 1
No 0
Unsure 2
99
E405. Does your partner usually use a condom? Never 0
Sometimes 1
Always 2
Declined to answer 99
E406. Have you disclosed your HIV status to Partner Family 
your partner and adult family members? Yes 1 1
NO 0 0
Declined to answer 99 99
Declined to answer
  
  
E407. Do any of your family members know that Partner Family 
you are taking medication for HIV (ARV)? Yes 1 1
NO 0 0
If the participants is not taking medication, N/A 98 98 →Go to E410.
Declined to answer 99 99
E408. Does anyone in your family regularly remind Yes 1
you to take your medication for HIV (ARV)? No 0
E409. During the past month, have you ever missed Yes 1
your medication for HIV (ARV) because No 0
you did not want your family members to find out? Declined to answer 99
E410. Have you ever experienced the following abuse 
from your family since the current pregnancy ?
(Ask one by one)
1) Verbal abuse Yes 1 No 0 Declined to answer 99
2) Physical violence Yes 1 No 0 Declined to answer 99
3) Separated or divorced
 from your partner
4) Forced to leave home Yes 1 No 0 Declined to answer 99
E411. Overall, how would you rate the support Poor 0
you receive from your family? Fair 1
Good 2
Excellent 3
F. Social Support:  
 Please answer about how you are supported by others
F401. Who is the most supportive person? Your partner 1
on your health problem Your parent 2
 (Select only one.) Your brother/sister 3
Your son/daughter 4
Your friend 5
Other: ( ) 6
Nobody 0
F402. How would you rate the care you receive from Poor 0
the health facility staff? Fair 1
Good 2
Excellent 3
F403. Do you regularly participate in a support group Yes 1
of people living with HIV? No 0 → Go to F405.
F404. Overall, how would you rate the support you Poor 0
receive from the support group? Fair 1
Good 2
Excellent 3
F405. Do you regularly receive home based care? Yes 1
No 0 → Go to F408.
F406. Does the home based caregiver regularly remind Yes 1
you to take your medication for HIV (ARV)? No 0
99Yes 1 No 0 Declined to answer
  
  
F407. Overall, how would you rate the support Poor 0
you receive from the home based care? Fair 1
Good 2
Excellent 3
F408. During the past month, have you ever felt bad Yes 1
because of things people did or said to you No 0
on account of your HIV status? Declined to answer 99
G. Belief of the effectiveness on HIV medication: 
Please answer how you believe the effectiveness 
of medication for HIV (ARV). Don't 
Know
G401 Taking medication for HIV (ARV) can help
keep HIV from being passed to the baby.
G402. The HIV medication that you are taking 
makes you healthier.
G403. If you do not take medications for HIV (ARV) 
properly, the medications won't work as well.
K. Feeding Practice:  
 Please answer how you think and practice feeding.
K401. Are you currently breastfeeding? Yes 1
No 0 → Go to K404.
K402. What else was the baby ever given to drink or eat? (Ask one by one)
1) Milk (Other than breast milk) Yes 1 Not 0
2) Infant formula Yes 1 Not 0
3) Plain water Yes 1 Not 0
4) Sugar water Yes 1 Not 0
5) Gripe water Yes 1 Not 0
6) Sugar-salt water solution Yes 1 Not 0
7) Fruit juice Yes 1 Not 0
8) Tea/Infusions Yes 1 Not 0
9) Honey Yes 1 Not 0
10) Other( ) Yes 1 Not 0
K403. If your baby tested HIV negative, 
which feeding option will you choose? Continue breastfeeding 0
Stop breastfeeding 1       Go to "L"
Unsure 2
K404. How long did you breastfeed? (weeks/months)
(If never breasrfed, write zero "0".)
K405. Why did you stop/not give breastfeeding?
I was afraid of HIV transmission to my baby through breastfeeding 1
My parents told me to stop/ not to give breastfeeding. 2
My partner told me to stop / not to give breastfeeding. 3
Other: Specify( ) 4
0 1
0 1
0 1
2
2
2
Disagree Agree
  
  
L. HIV test for baby:
 Please answer about HIV test for your baby.
L401. Has your baby ever been tested for HIV? Yes, tested. → Go to "M"
(dd/mm/yyyy)
Never tested 0
L403. Why your baby was not tested for HIV? (Ask one by one.)
1) Health workers did not inform you about HIV test for your baby. Yes 1 No 0
2) You did not know why your baby should be tested. Yes 1 No 0
3) You did not know when your baby should be tested. Yes 1 No 0
4) You did not know the place where your baby should be tested. Yes 1 No 0
5) You were afraid of knowing the HIV status of your baby. Yes 1 No 0
6) You thought your baby looked healthy. Yes 1 No 0
7) You were afraid of stigma against your baby. Yes 1 No 0
8) Taking your baby to HIV test on another day was tiring. Yes 1 No 0
9) You were too busy to take your baby to HIV test. Yes 1 No 0
10) You had no transportation to take your baby to HIV test. Yes 1 No 0
11) You had no money  to take your baby to HIV test. Yes 1 No 0
12) Other: Specify )
M. Family Planning:  
 Please answer about various ways or methods that 
 a couple can use to delay or avoid a pregnancy.
M401. Do you want to have more children? Yes 1
No 0
M402. Did any health workers tell you about any methods to delay Yes 1
 or avoid pregnancy after the delivery? No 0
M403. Are you currently using any method to delay Yes 1
or avoid getting pregnant? No 0 →  Go to M405.
M404. If Yes at M403,  what method are you using?
(Ask one by one) 1) Male condom Yes 1 No 0
2) Pill Yes 1 No 0     After answer, 
3) Injection Yes 1 No 0      Go to "H".
4) Other ( )
M405. If No at M403 , why don't you use any methods to delay or avoid a pregnancy (=FP methods)? (Ask one by one)
1) You do not know any FP methods. Yes 1 No 0
2) You do not know where you can get a FP method. Yes 1 No 0
3) You do not ask health worker for a FP method. Yes 1 No 0
4) Your religion does not allow to use a FP method. Yes 1 No 0
5) You are afraid of health problems (side-effect). Yes 1 No 0
6) You do not want to use a FP method . Yes 1 No 0
7) Your partner does not want to use a FP method. Yes 1 No 0
8) You used a traditional method instead. Yes 1 No 0
9) You are breastfeeding. Yes 1 No 0
10) You want to have more children. Yes 1 No 0
11) Other : Specify ( )
  
  
M406. Do you want to use any method Yes 1
 to delay or avoid a pregnancy in the future? No 0
H. ART clinic visit: New HIV+ mothers & Already known HIV status but not yet on ART mothers
Please answer about starting HIV treatment
H401 When did you know your HIV positive status?
Before this pregnancy 1
During this pregnancy 0 → Go to H403.
H402 Please answer about "before the current pregnancy" one by one.
1) Before the current pregnancy , did you regularly attend ART clinic? Yes 1 No 0 All=No, Go to H403.
2) Before the current pregnancy , have you already had your ART card? Yes 1 No 0  1) or 2) =Yes but 3)=NO, 
3) Before the current pregnancy , have you already been on ART? Yes 1 No 0     go to H403.
3)=Yes, go to "N".
H403. Did health workers tell you to go to ART clinic Yes 1
for blood test / treatment? No 0
H404. Did you have blood test (for CD4)? Yes 1
No 0 → Go to H410.
Don't know 2
H405. When was the test? (mm) (yyyy)
H406. Which facility? (Name of health facility)
H407. Did you receive the results of blood test? Yes 1
No 0
Don't know 2
H408. After you received the result… (Ask one by one.)
1) You were given another appointment
    for another test after (days/week/months) Yes 1 No 0
after (days/weeks/months)
2) You were given an appointment
     to start lifelong treatment Yes 1 No 0
     after(days/weeks/month) after (days/weeks/months)
3) You started lifelong treatment Yes 1 No 0
Started on (dd/mm/yyyy) → Go to "N"
H409. If answer is NO at H407,  what were the reasons for not receiving the result of blood test?
The result was not ready  1
I didn't go back to receive results  2          Go to "N"
Others (specify )  3
  
  
H410. Why didn't you go for blood test (ART clinic)?  (Ask one by one.)
1) Health workers did not inform you to visit ART clinic. Yes 1 No 0
2) You did not know why you should go to ART clinic. Yes 1 No 0
3) You did not know when you should go to ART clinic. Yes 1 No 0
4) You did not know the place where you should go to ART clinic. Yes 1 No 0
5) You did not believe your HIV status. Yes 1 No 0
6) You thought treatment for HIV is harmful. Yes 1 No 0
7) You felt healthy without treatment. Yes 1 No 0
8) You thought HIV can not be cured by treatment. Yes 1 No 0
9) You were afraid of stigma. Yes 1 No 0
10) You were scared of the marriage ending. Yes 1 No 0
11) Visiting ART clinic on another day was tiring. Yes 1 No 0
12) Visiting another facility for ART clinic was tiring. Yes 1 No 0
13) You were too busy to visit ART clinic. Yes 1 No 0
14) You had no transportation to visit ART clinic. Yes 1 No 0
15) You had no money  to visit ART clinic. Yes 1 No 0
16) Other: (Specify )
N. Adherence to HIV medication (ARV) :  6 weeks to 5 months after delivery
N401. During this pregnancy and after this delivery, do (did) you take Yes 1
the medication for HIV? No 0 →  Go to "P"
N402. How many times  do (did) you take medication per day ? times
N412. During pregnancy , how much did you MISS  HIV medications ?
   Using a line below, please point at approximate amount of medication  you took.
   Interviewer puts a tick where the participant points.
N413. During labour and delivery , Yes 0
did you take medication for HIV (ARV)? No 1
Unsure 2
N414. Regarding the 7-days HIV medication (ARV) just after delivery,
how many days did you Miss ?
Note: If you miss at least once in a day, it is counted as 1day.
N415. Most medications need to be taken on a schedule .  For example "2 times a day" or "every 12 hours".
How many days did you Miss  your specific schedule   for the 7-days HIV medication just after delivery ?
Please answer about medications for HIV (ARV) that you may have missed taking over the last 4 days.
We understand that many people on medications for HIV (ARV) find it difficult to take it regularly, 
and often missed doses.  We won't be surprised if you have missed lots of doses as well.
The questions below are only for women on lifelong treatment (ART).
If the participant is not on the treatment (ART), Go to N410.
  
  
N404. Missed Medication:
How many times did you miss  during the last 4 days?
 Note that the table asks about TIMES , not the numbers of PILLS .
Never missed = 0 Yesterday 2 days ago 3 days ago 4 days ago
Once missed   =1 times times times times
Twice missed = 2 missed missed missed missed
N405. Missed Time Schedule:
Most medications need to be taken on a schedule ,
For example, "twice a day" or "every 12 hours".
How often did you miss  your specific schedule
over the last 4 days? 
 (Select only ONE) Never Some About Half Most All
0 day 1 day 2 days 3days 4 days
0 1 2 3 4
N408. Last Time Missed: Within the past week 0
When was the last time  you missed 1-2 weeks ago 1
any of your medications? 2-4 weeks ago 2
 (Select only ONE) 1-3 months ago 3
More than 3 months ago 4      Go to N411.
Never skip medications 5
N409. Adherence in the past 30 days
Tick in the blank below at the point showing you best guess about
HOW MANY DAYS you have MISSED any medications in the last 30 days.
For example, if you missed 2 days, you tick in a blank of  "1-3 days" 
   Note: If you miss at least once in a day, it is counted as 1day.
N410. If you missed your medications in the last 30 days , what were the reasons?
     If your medication for HIV has finished 7 days after delivery, please answer about 
     the last 30 days before ending HIV medication.
(Ask one by one.)
1) You simply forgot. Yes 1 No 0
2) You were away from home. Yes 1 No 0
3) You were busy with other things. Yes 1 No 0
4) You had a change in daily routine. Yes 1 No 0
5) You fell asleep/slept through dose. Yes 1 No 0
6) You had problems taking  medications at specific time. Yes 1 No 0
7) You felt sick. Yes 1 No 0
8) You wanted to avoid side effects. Yes 1 No 0
9) You felt depressed/ overwhelmed. Yes 1 No 0
10) You had too many pills to take. Yes 1 No 0
11) You did not want others to notice you taking drugs. Yes 1 No 0
12) You felt drug was toxic/harmful. Yes 1 No 0
13) Your partner interfered with your medication. Yes 1 No 0
14) You did not have enough food. Yes 1 No 0
15) Other( )
N411. Refill record since the first antenatal  visit of the current pregnancy  (dd/mm/yyyyy)
Vis i ted date 5
1 6
2 7
3 8
4 9
  Write a number
in each blank ➙
  
  
P. Baby Adherence: 6 weeks to 5 months after delivery
Please answer about medication for your baby.
P401. Currently does your baby take Septrin? Yes 1
No 0
Unsure 2
P402. Mother's knowledge on baby's medication Yes 1 →Go to P404.
Currently does your baby take medications for HIV ? No 2
(medication other than Septrin)? Unsure 3
P403. Confirmation of giving HIV medication to baby
Please show me the medicine for your baby. The baby has Nevirapine 1
 (Please check the register book as well.) The baby doesn't have Nevirapine 0 →End the interview.
P404. Who mainly gives HIV medication to your baby? Yourself 1
Your partner 2
Other ( ) 3        Go to P408.
P405. Does anyone in your family regularly remind you Yes 0
to give medication for HIV (ARV) to your baby? No 1
P406. Is it difficult for you to understand a little a l ittle
the instruction of how to give Easy Difficult
HIV medication to your baby? 0 1 2 3
P407. Is it difficult for you to use a syringe a little a l ittle
 when giving HIV medication Easy Difficult
 to your baby? 0 1 2 3
P408. For the HIV medicaton (NVP) of your baby, 
How much do you give the HIV medication per 1 time? ml per 1 time
P417. Regarding 6-weeks HIV medication  since your baby started medications,
how much HIV medications did your baby MISS ?
Using a line below, please point at approximate amount of medication  your baby took.
(Interviewer puts a tick where the participant points.
The next questionnaire asks about medication for HIV (ARV)
that your baby has MISSED to take over the last 4 days.
We understand that many mothers find it difficult to give it to their babies regularly.
 We won't be surprised if your baby have missed lots of doses as well.
P409. Missed Medication:
How many TIMES  did your baby MISS  to take the medications
 in the last 4 days ? (Fill in each blank)
Never missed = 0 Yesterday 2 days ago 3 days ago 4 days ago
Once missed   =1 times times times times
Twice missed = 2 missed missed missed missed
Easy Difficult
Easy Difficult
  Write a number
in each blank ➙
  
  
P410. Missed Time Schedule:
Most medications need to be taken on a schedule.  For example taking at specific time.
How often did you MISS  the specific schedule for your baby over the  last 4 days ?
 Never Some About Half Most All
0 day 1 day 2 days 3days 4 days
0 1 2 3 4
P413. Last Time Missed:
When was the last time  your baby  MISSED  any of HIV medications?
 (Select only ONE.) Within the past week 0
1-2 weeks ago 1
2-4 weeks ago 2
More than 4 weeks ago 3
Never skip medication 4 ➙Go to P416.
P414. Adherence since baby starting medication for HIV (ARV):
Tick in the blank below at the point showing you best guess about
HOW MANY DAYS  your baby  have MISSED  any medications in the last 30 days .
For example, if your baby missed 2 days, you tick in a blank of  "1-3 days" 
     Note: If your baby miss at least once in a day, it is counted as 1day.
P415. If you missed  giving HIV drugs to your baby in the last 30 days ,
what are the reasons? (Ask one by one)
1) You simply forgot. Yes 1 No 0
2) You were away from home. Yes 1 No 0
3) You were busy with other things. Yes 1 No 0
4) You had a change in daily routine. Yes 1 No 0
5) Your baby fell asleep/slept through dose. Yes 1 No 0
6) You had problems giving  medications at specific time. Yes 1 No 0
7) Your baby was sick. Yes 1 No 0
8) You wanted to avoid side effects. Yes 1 No 0
9) You felt depressed/ overwhelmed. Yes 1 No 0
10) Your baby had too many medications to take. Yes 1 No 0
11) You didn't want others to notice your baby taking medicine. Yes 1 No 0
12) You felt drug was toxic/harmful for your baby. Yes 1 No 0
13) Your partner interfered with giving the medication to your baby. Yes 1 No 0
14) Your baby did not take enough milk/fluid. Yes 1 No 0
15) Other( )
P416. Refill record since baby was born (dd/mm/yyyy) Vis i ted date
1
2
3
4
5
6
End of the interview  :  Thank the woman, give a soap, and make a next appointment.
  
Appendix 7. Informed Consent Form 
Explanation Sheet 
MoH Zambia – JICA SHIMA project-The University of Tokyo 
Prevention of mother-to-child transmission of HIV and its linkages to ART Services in 
Chongwe 
The purpose of this study is to assess current situation of HIV care, support and treatment for 
pregnant women/mothers and babies in the district in order to improve services provided in the 
district.  We would like you to participate in the study.  What we learn from you will contribute 
to improve prevention of mother-to-child HIV transmission services in Zambia and other 
countries in the future. 
 If you agree with this study, we would like you to participate in the interviews during 
pregnancy, 7 days, 6 weeks, and 6 month after delivery.  In each interview, we will ask you 
about your background, health condition, your baby’s health condition, clinical information, 
care, treatment, and medication.  We would like to see your antenatal card, children’s clinic card, 
and medical record. 
We would like to inform you that your response will be kept confidential. The information 
will not be communicated to anyone except the research team. You will be interviewed 
privately at your comfort. Although your participation is much appreciated, your participation is 
voluntary and you are free to withdraw from the study at any time and all the data will be 
deleted at the time of your withdrawal. Your participation and response will not affect the 
quality of care you receive at the care facility. Please read next page and if you agree then sign 
the document. If you feel comfortable and allow us, I would like to start the interview. It will 
take about 40-50 minutes. If you have any questions or concerns about the study please don’t 
hesitate to contact the following address as given below.  
We will highly appreciate your support.  Thank you for your cooperation. 
 
 Charles Msiska (Director, Chongwe District Health Office) 
Chongwe District Health Office   Tel: 211-620-023 
 Naoko Ishikawa (Chief Advisor, SHIMA project / MoH Zambia - JICA) 
 Ministry of Health, Ndeke House, P.O.Box 30205, Lusaka  Tel&fax: 211-257-728 
 The University of Zambia Research Ethics Committee 
Ridgeway Campus P.O. Box 50110 Telex: UNZALU ZA 44370   
Telegrams: UNZA, LUSAKA Tel: 260-1-256067  Fax: + 260-1-250753   
 Masamine Jimba, Sumiyo Okawa (The University of Tokyo) 
    7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan   Tel: +81-3-5841-3698 
  
  
Informed Consent Form 
 
I acknowledge that: 
 
・ I have been given all the information regarding the research. 
・ I have been told that confidentiality and privacy will be maintained, and any information I 
will give will not be disclosed by any means. 
・ I and my child are not under any pressure to contribute to the research. 
・ I clearly know that I and my child can quit answering questions at any stage and no action 
will be taken against me and my child. 
・ I am satisfied with the information given. 
 
□ I agree to participate in the study.  
□ I agree my child to participate in the study.  
 
Name:                                    Signature:                                 
 
 
Name (Researcher):                         
 
Date(dd/mm/yy):                            
 
Please note: 
If you need any information, please do not hesitate to contact the following address as given 
below: 
 Charles Msiska (Director, Chongwe District Health Office) 
Chongwe District Medical Office   Tel: 211-620-023 
 Naoko Ishikawa (Chief Advisor, SHIMA project / MoH Zambia - JICA) 
 Ministry of Health, Ndeke House, P.O.Box 30205, Lusaka  Tel&fax: 211-257-728 
 The University of Zambia Research Ethics Committee 
Ridgeway Campus P.O. Box 50110 Telex: UNZALU ZA 44370   
Telegrams: UNZA, LUSAKA Telephone: 260-1-256067   Fax: + 260-1-250753  
 Masamine Jimba, Sumiyo Okawa (The University of Tokyo) 
    7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan   Tel: +81-3-5841-3698 
  
Appendix 8: Ethical Approval by the Research Ethics Committee  
of the University of Tokyo 
  
  
  
  
Appendix 9: Ethical Approval by the Biomedical Research Ethics Committee  
of the University of Zambia 
  
  
  
  
  
  
 
  
 
